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moiety in streptothricin F was investigated using a combined approach of whole-
cell incorporation experiments and cell-free extract studies.
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flasks of S. L-1689-23.Analysis of the purified streptothricin F by 13C NMR
revealed a 1.9% enrichment of the guanidino carbon (C-6) of STF. Based upon
these results, further support for a convergent biosynthesis of STF has been
obtained.
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Chapter 1
Introduction to Arginine Secondary Metabolism in Streptomyces
Iavendulae var. L-1 689-23
Examples of Arginine Metabolism in Various Streptomyces Species
The use of amino acids in the formation of secondary metabolites is quite
abundant in nature. These metabolites can range from alkaloids, derived from
tyrosine or tryptophan, to cyclic peptide antibiotics, containing both the twenty
common amino acids and more unusual amino acids,to aminoglycoside
antibiotics.Arginine is the most basic amino acid, and has been incorporated
into a number of natural products. Examples of the incorporation of arginine by
Streptomyces species are especially interesting.Some examples show only
slight modification of the arginine molecule while others show such extensive
modification that, at first hand, arginine would not be considered the most direct
primary precursor.
Blasticidin S (1), an antifungal antibiotic produced by Streptomyces
griseochromogenes,containsa ö-N-methylated-arginineresidueinits
structure. Work by the Gould group has shown direct incorporation ofarginine1
(2) and3-arginine2(3) into I as shown in Scheme 1.1.N-Methylation was
originally proposed to occur as the last step in the biosynthesis ofi.3But this
hypothesis was recently modified by work from our laboratory. Leucyiblasticidin
S (Leu-BS), modified by the addition of leucine to the n-nitrogen of the 3-arginine
portion of 1,is formed prior to N-methylation and acts as a self-resistance
mechanism.4As the molecule is transported out of the cell, the leucine residue is
most likely removed to liberate the active antibiotic.2
Scheme 1.1. Incorporation of Arginine Into Blasticidin S
NH2 H
H2NyAyOH H2NyN yOH
NH
NH NH2O
2 3
HO2C 0
CH3
H N
H2NT
N"
NH NH2O
Blasticidin S, I
An example of near-intact incorporation of arginine into a secondary
metabolite can be found in sinefungin (4), a nucleoside antibiotic produced by S.
griseolus and S. incarnates. Both arginine (2)and ornithine(5)6are
incorporated into 4 using cell-free extracts of S. incarnates and S. griseolus,
respectively (Scheme 1.2).Pyridoxal phosphate was required in the enzyme
assays and was proposed to activate arginine for coupling with C-6 of ribose. A
mechanism for the activationof arginine via formation of a Schiff-base
intermediate with pyridoxal phosphate and its incorporation into 4 has been
proposed by Malina and coworkers.53
Scheme 12. Incorporation of Ornithine and Arginine Into Sinefungin
NH2 H2N,, 0Ad
H2N 2
Ornithine, 5 HO2C NH2
Sinefungin
4
The aminoglycoside antibiotic, streptomycin (6, Scheme 1.3) contains two
guanidino moieties that are derived from arginine.The biosynthesis of 6 has
been extensively studied and most of the enzymes utilized in the formation of
streptomycin have been identified by several differentgroups.79'1°The gene that
codes for the amidinotransferase StrBl from S. griseus has been isolated and
characterized.11The gene product catalyzes the amidination of scyio-inosamine
4-phosphate (7)into N-amidino-scy//o-inosamine 4-phosphate (8) andN1-
amidinostreptoamine 6-phosphate (9) into streptidine 6-phosphate (10).The
crystal structure of StrBl was recently reported and indicated that conserved
residues in the active site of the enzyme shared equivalent topological positions
to that of other amidinotransferases(AT).12The authors therefore suggested a
similar mechanism among AT.4
Scheme 1.3. Partial Biosynthetic Pathway of Streptomycin
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Probably the best example of the extensive metabolism of arginine into a
secondary metabolite is the 3-lactamase inhibitor, clavulanic acid (11), a 1-
lactam produced by S. clavuligerus. As depicted in Scheme 1.4, most of the
biosynthetic intermediates in clavulanic acid biosynthesis have beenidentified13
15as well as several of theenzymes.16The initial C-3 unit that is condensed with
arginine has yet to be identified, however, strong evidence has beenreported17
suggesting that pyruvate is the primary C-3 precursor.Scheme 1.4. Biosynthesis of Clavulanic Acid From Arginine
NH
Arginine
H2NNH
[Ho2C]
HNJ
[
Pyruvate
HO CO2H
0
NH
H2N NH
PNOH
CO2H
CO2H
Clavaminic Acid
NH
H2N NH
CO2H
NH2
QOH
CO2H
Proclavaminic Acid
pOH
CO2H
Clavulanic Acid, Ii
5
Our laboratoryisactively involvedinstudying the biosynthesis of
secondary metabolites containing basic amino acids. One of these compounds,
blasticidin S, has already been discussed. Two other compounds, which will be
discussed in greater detail, are steptothricin F and capreomycin, antibiotics
produced by two different Streptomyces species; S.Iavendulaeand S. capreolus,
respectively.Isolation of Streptothricin F and Related Homologs
Streptothricin F (STF,12a)is a broad-spectrum peptidyl nucleoside
antibiotic first isolated from StreptomycesIavendulaein 1943 by Waksman and
Woodruff.18Itis a member of the Streptothricin class of antibiotics; the only
difference among the members is the number of-lysine residues present
(Figure 1.1).
0 H9H
OH H2N'O,N<
)ii
12a:Streptothricin F;n= 1
12b:Streptothricin E;n= 2
12c:Streptothricin D;n3
12d:Streptothricin C;n4
12e:Streptothricin B;n= 5
12 f:Streptothricin A;n= 6
12g:Streptothricin X;n= 7
Figure 1.1.The Streptothricin Class of Antibiotics
Because of their wide-spread occurance and potent biological activity, it
was thought that several different streptothricin analogues had been isolated.
For most cases, however, it was determined that the compounds were actually a
mixture of the streptothricin antibiotics. A list of the many Streptomyces strains
as well as other variants of S.Iavendulaethat produce streptothricins have been
summarized inthe thesis of JohnWityak.'9While several streptothricin
producersarevariantsofS.Iavendulae,otherstrainssuchasS.
xanthophaeus,20'2"22S.purpeofuscus2325and S.roseochromogenes26are also
representatives of the diverse species of Streptomycetes that produce these
antibiotics.7
Biological Activity of the Streptothricin Group of Antibiotics
Streptothricin F and its homologues exhibit a broad spectrum of biological
activity. The streptothricins show antibacterial activity toward both Gram-positive
and Gram-negativebacteria,mycobacteria,as wellas some antifungal
activity.27'18A cocktail of streptothricins (streptothricins A-E) has also been
reported to showin vitroantiviralactivity.28Besides microorganisms and lower
eukaryotes, the streptothricins have demonstrated toxicity towardsinsects29'30
and some species offish.29
The streptothricin class of antibiotics, while exhibiting very broad activity,
is not used clinically due to its high toxicity, which has been observed in mice and
rats. The streptothricins were first shown to exhibit an increase in protein binding
to serum proteinsin vitroin relation to an increase in the number of-lysine
residues in themolecule.31It was later reported that kidney damage was found
to result from the formation of the free acid of the streptothricins (Figure 1.2)
which had been isolated from the urine of mice andrats.32'33The streptothricins
were reported to have no hematotoxicpotential.34The use of the streptothricins
as taeniacidal agents in dogs and cats has beenreported,35'36but they are not
currently used in veterinary medicine.
0 OH
H2NAO-OH
HFII
OHNH NH2 (ONH )nH
Figure 1.2. Proposed Toxic Metabolite of the StreptothricinsThe mode of action of the streptothricins has been reported in some detail.
The streptothricins were first reported to form weak DNA-antibiotic complexes in
low saltconcentrations.37It was later reported that antibiotics, streptothricin F
(12a), effected protein synthesis by binding to the 30S and 50S subunit of the
bacterialribosomes,38'39thus preventing the amino acid-tRNA from binding to the
mRNA-ribosome complex.
Chemical and Physical Properties of Streptothricin F (12a)
The streptothricins are solids that decompose upon melting above 250 °C.
During the isolation and purification of the streptothricins, several salts have been
reported such as thehelianthate,40'4' picrolonate,4° reineckate,40'4'picrate,4°
sulfate,42 phosphotungstate,4°andhydrochloride.40'41
Streptothricin F has three ionizable groups with pKa's of 7.1, 8.2, and
The antibiotic is insoluble in organic solvents with the exception of slight
solubility in methanol and dimethylsulfoxide.It is completely soluble in water at
pH ranges of 1-9, but substantial decomposition occurs at higher or lower pH.
The hydrochloride salt of Ia can be stored for over a year at -10 °C in a
dessicator without appreciable decomposition.For long-term storage of STF,
formation of the helianthate salt, which can be stored in a dessicator at 25 °C, is
preferred.
Over the years, several researchers have assigned partial 1HNMR44'45
and 13CNMR23'46'47spectra of STF (12a) or its components.Martinkus48was the
first to assign the complete 1H and 13C NMR spectra of 12a as presented in
Table 1.1.Table 1.1. Proton and Carbon Chemical Shift of STF (12a) at pH 6.8°
Proton Mult.6(ppm) J (Hz) mt.CarbonMult.(ppm)
I s167.29
2 d 4.66 14.2 1 H 2 d51.80
3 dd 4.12 <1, 13.6 1 H 3 d58.34
4 bs 4.76 1 H 4 d58.17
5 (pro S) dd 3.85 4.9, 14.6 1 H 5 t46.56
5 (proR) dd 3.45 <1, 14.6 1 H
6 s159.94
7 d 5.14 9.3 1 H 7 d76.25
8 dd 4.29 2.9, 9.8 1 H 8 d46.35
9 dd 4.21 2.9, 3.4 1 H 9 d63.88
10 dd 4.83 <1, 3.4 1 H 10 d67.38
11 dt 4.38 <1,5.9 1 H 11 d70.79
12 d 3.77 5.7 2 H 12 t 57.64
13 s155.08
14 s169.75
15 (pro S) dd 2.66 8.3, 16.6 1 H 15 t 33.83
15 (proR)dd 2.78 4.4, 16.6 1 H
16 m 3.65 1 H 16 d45.67
17 bs 1.79 2H 17 t 26.51
OH 0 HH
OHH2NON6
riii
OHNH NH2
NH2
0 15 17
Streptothricin F
(12a)10
Structural Elucidation of Streptothricin F (12a)
The structure of streptothricin F was initially elucidated from the hydrolysis
products of the antibiotic. Three basic components were isolated after vigorous
hydrolysis andpurifiedby various chromatographic techniques.These
components were identified as the amino sugar D-gulosamine (13), and the basic
amino acids f-lysine (14) and streptolidine(15)23424954(Figure 1.3).The
structures of13555657 14,58and155960were confirmed by total synthesis, and the
absolutestereochemistryofstreptolidine(15)was determinedby x-ray
crystallography.61
OH NH2
D-Gulosamine
13
OH NH2
NH
-Lysine
14
OH HH;
NH2
HN<içH
Streptolidine
15
Figure 1.3. The Structural Components of the Streptothricin Class of
Antibiotics
Under mild hydrolysis of STF (12a) it was found that carbon dioxide and
ammonia weregenerated.42It was proposed that a urethane substituent was
present on either the C-3 orC-4hydroxy group of the gulosamine moiety in
STF.43The complete structureof 12a was finallyelucidated by total
synthesis59'62which confirmed the location of the carbamate substituent at C-4
of gulosamine. The Gould group also independently determined the location of
the urethane as residing atC-4.4811
Previous Biosynthetic Studies on the Streptolidine Moiety of STF
In the mid 1 970s, two differentgroups47'63'64began biosynthetic studies on
12a which produced conflicting results. Sawada and co-workers concluded that
two different pathways leading to the formation of streptolidine(15)were present
in Streptomyces species:one derived from arginine (2) and the other from
acetate. The use of universally labeled materials made it difficult to determine
the specificity of incorporation as well as which pathway was involved in the
biosynthesis of15.Sodium [1-13C}- and [2-13C]acetates were specifically
incorporated, however, Sawada and co-workers were unable to propose a
pathway that explained the observed labeling pattern in12a.47Gould and co-
workers disputed the proposal that two different pathways were used in the
formation of15.65Using [1,2-13C]acetate,they found that 12a was specifically,
albeit indirectly, labeled via arginine (2) and the Tricarboxylic Acid Cycle (TCA).
This result strongly supported a single pathway for the formation of15as shown
in Scheme 1.5.Scheme 1.5. Labeling of Streptolidine by [1 ,2-13C]Acetyl-00A via
a-Ketoglutarate and the TCA Cycle
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In1972,BycroftandKing61proposedtheintermediacyofa
dehydroarginine derivative (16) and the amino acid, capreomycidine (17), in the
biosynthesis of 15 as shown in Scheme 1.6. The [1 ,2-13C]acetate incorporation
study supported the proposed pathway in Scheme 1.6 as well as suggesting the
direct biosynthesis of capreomycidine from arginine.Scheme 1.6. Biogenesis of the Streptolidine Portion of Streptothricin F
from Arginine (2)
HNy
H2N
H2NOH
2
HN1
H2
H2N0H
HN(1
H20H
15
1K]
Additional support for Bycroft and King's proposal was obtained through
dual-labelingstudiesusingL-[guanidino-13C,15N2]- and DL-[guanidino-13C,2-
15N}arginine.66The incorporation of 13C and 15N into 12a was observed as shown
in Scheme 1.7. Spin coupling between 13C and 15N demonstrated the formation
of two new C-N bonds and established that all three guanidino nitrogen atoms in
streptolidine are derived from arginine.It was also determined that onlyL-
arginine is incorporated into streptothricin F (12a) further supporting the direct
incorporation of arginine into 15 and 12a.14
Scheme 1.7. Incorporation of L-[guanadino-'3C,5N2}- and
DL-[guanidino-' 3C,2-' 5N]Arginine Into I 2a.
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The remaining two new C-N bonds formed in the conversion of arginine to
the streptolidine moiety in 12a were identified through incorporation studies using
DL-[1-13C,5-15N]- andDL-[3-13C,guanidino-15N2]arginines (Scheme I.8).67Scheme 1.8. Incorporation of DL-[1-13C,5-15N]- and
DL-[3-1 3c,guaniciino-1 5N]Arginine Into I 2a.
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While Bycroft and King's proposal of a Michael addition to dehydroarginine
(16) was a plausible mechanism, other possibilitiesfor the formation of
streptolidine (15) wereproposed.67As Scheme 1.5 illustrates, sequential
oxidation of arginine to-hydroxyarginine (18) then 3-ketoarginine (19) then
followed by formation of an imine intermediate would occur.Subsequent
reduction of the imine could lead to capreomycidine (17). Alternatively, activation
of 18 as a phosphate ester followed by nucleophilic displacement with the
terminal guanidino nitrogen could also lead to 17.16
Scheme 1.9. Alternative Mechanisms for Streptolidine Formation in 12a
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To distinguish between the three different pathways, incorporation studies
using DL-[2-2H]-, DL-[3,3-2H2]-, and DL-[2,3,3-2H3]arginines wereconducted.67In
each example, the isolated streptothricin F showed no deuterium incorporation.
These negative results were interpreted as support for the formation of-
hydroxy- and-ketoarginine because the loss of deuterium at C-3 could be
explained by the formation of a keto group, while loss of deuterium at C-2 could
result from simple enolization of the f-dicarbonyl moiety.17
Further exploration of the fate of the arginine hydrogens was conducted by
performing an incorporation study using DL-[2,3,3,5,5-2H5]arginine (20, Scheme
1.1O).68It was found that deuterium was completely lost from C-2 and C-3, but
was retained at C-5. These findings substantiated the earlier results in which
deuterium was lost from C-2 and C-3.
Scheme 1.10. Incorporation of DL-[2,3,3,5,5-2H5]Arginine (20) Into the
Streptolidine Portion of STF (12a)
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When erythro- and threo-DL-[5,5-2H2]--hydroxyarginine were introduced
to production cultures of S. L-1689-23, no deuterium was observed in the
isolated streptothricin F, and isotope-trapping experiments failed to detect de
novo biosynthesis of either 13-hydroxy- or 13-ketoarginine.
The stereospecific oxidation of arginine to form the hydroxyl group in
streptolidine was examined next using DL-[4,4-2H2]-, L-[4,4-2H2]-, L-[4S-2H]-, and
L-[4R-2H]arginines (21, Scheme 1.11).Results of these incorporation studies
indicated retention of the pro-4R hydrogen at what had been C-4 of arginine.iI
Scheme 1.11. Incorporation of L-[4R-2H]Arginine (21) Into the
Streptolidine Portion of STF (12a)
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Previous Biosynthetic Studies on the l-Lysine Moiety of STF
Initial work by Sawada and coworkers first reported the incorporation of a-
lysine (22) into the-Iysine (14) portion of streptothricinF.63This finding was
later indirectly supported by Gould et al.in their incorporation studies using
labeledacetate.65One question that remained was how -lysine is formed from
a-lysine, 22.3-Lysine has been identified as a degradation product from various
species ofClostridium.69The enzyme responsible forthisconversion,
Clostridium (S)-a-lysine 2,3-aminomutase, has been isolated and cofactor
requirements werereported.7°Recently, the gene for lysine 2,3-aminomutase
(KAM, EC 5.4.3.2.) from Clostridium subterminale SB4 has been cloned and
sequenced.71This enzyme catalyzes the stereospecific migration of the 3-pro-R
hydrogen of 22 with inversion of configuration at both C-2 andC-3.72Recently,
Chen and coworkers have reported on a lysine 2,3-aminomutase encoded by the
yodO gene of Bacillussubtilis.73
To confirm the direct incorporation of 22 into the fE-lysine portion of
streptothricin F, Gould and Thiruvengadam synthesized DL-[3-' 3C,2-'5N]lysine
(23, Scheme 1.12) and introduced it to production flasks of S.L-1689-23.74
Analysis of the "3C NMR spectrum of isolated 12a showed clear incorporation ofiE]
labeled material as well as the formation of a new 13C-15N bond. Because a
15N spin coupling was observed in derived 12a, the result clearly showed that the
migration of nitrogen from C-2 to C-3 in 22 was intramolecular.
Scheme 1.12. Incorporation of DL-[3-13C,2-15N]Lysine (23) Into the
-Lysine Portion of STF (12a)
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To determine whether the 2,3-aminomutase used in the biosynthesis of
streptothricin F utilized the same mechanism as the Clostridium enzyme, a-
[(3RS)-2H2]-, a-[(3R)-2H]- and a-[(3S)-2H]lysine (22a, 22b and 22c, respectively,
Scheme 1.13) were tested.75 From the analysis of the 2H NMR spectra of the
derivedantibioticfromtheindividualincorporationexperiments,itwas
determined that the migration of the alpha nitrogen proceeded through inversion
of configuration at C-3 via an intramolecular process.The migration of the 3-
pro-R hydrogen to C-2 was also demonstrated to occur with an inversion of
configuration.Lastly, the incorporation of-[(2S)-2H]lysine was observed in the
-lysine portion of 12a suggesting that 14 is a true intermediate in the formation
of 12a.7520
Scheme 1.13. Incorporation of Deuterated Lysine Into the-Lysine
Portion of 12a
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Previous Biosynthetic Studies on the Gulosamine Moiety of STF
The origin of the gulosamine moiety (13) in 12a was initially addressed by
Sawada andcoworkers47'63in the late 1970's.Glucose (23) and glucosamine
(24) were identified as precursors by adding [U-14C]-D-glucose and [1-14CJ-o-
glucosamine to production cultures of S.Iavendulae,and observing in 0.71% and
4.46% incorporation into 12a, respectively. The higher level of incorporation of
labeled glucosamine, with respect to labeled glucose, suggested that 24 was a
more direct precursor to 13.Radioactivity was also found in the-lysine and
streptolidine portions of 12a as well, implying extensive degradation of glucose.21
D-GIucose
(23)
D-GIucosamine
(24)
D-Gulosamine
(13)
Figure 1.4. The structure of D-Glucose (23), D-Glucosamine (24) and
D-Gulosamine (13)
Palaniswamy andGould76establishedD-glucosamine asadirect
precursor of streptothricin F by observing the direct incorporation of [2-13C,15N]-D-
glucosamine (25) into the gulosamine moiety of 12a (Scheme 1.14). To probe
the conversion of glucose to 13, [1-2H]- and [2-2H]-D-glucose (26 and 27,
respectively) were tested and the resulting STF was analyzed by 2H NMR. While
theincorporationstudyusing[i-2H]-D-glucoseshowedreasonable
incorporation(i.8%) into H-8 of 12a, and minor incorporation (0.4%) into the
f-
lysine residue at H-I 7/H-I 8, [2-2H]-D-glucose resulted in only minor incorporation
(0.09%) at H-i 7/H-i 8 further illustrating the extensive degradation of glucose and
random redistribution of label into streptothricin F (12a). From these results, it
was proposed that H-2 of glucose is lost in the phosphoglucose isomerase
reaction.22
Scheme 1.14. Incorporation of Labeled Glucose and Glucosamine Into
STE (12a)
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Objectives and Significance of the Present Studies
Through work that has been done as of 1994, our understanding of the
biosynthesis of streptothricin F can be summarized as shown in Scheme 1.15.
Gould has demonstrated that key components of streptothricin F, namely-
lysine74(14) andD-glucosamine76(13) are formed prior to assembly of the
antibiotic suggesting a convergent biosynthesis of 12a.Extensive work in the23
area of arginine metabolism in STFbiosynthesis6568provided insight into the
conversion of arginine into the streptolidine portion of STF.Streptolidine (15),
however, has not been identified as a true intermediate in the biosynthesis of
12a.Through the use of 13C-15N dual labeling studies, the amino acid,
capreomycidine (17) has been proposed as an intermediate in the formation of
streptolidine but has not been unequivocally shown to be a true intermediate.
Scheme 1.15. Proposed Biosynthetic Pathway to STE (12a) as of 1994
HN*
H2N(0H H2N0H
[HH2Oj
24
0 OH
H2NAO
HH
-OH N-J-
__ N=<J)
HRII
OHNH NH2
N H
12a
HOH
OH HH-
NH2
HN<t
HO2C,,NH2
NH2
22
OH NH2
NH2
1424
The first objective of this work was to determine whether streptolidine is an
intermediate in the biosynthesis of STE.This would conclusively determine
whether STF biosynthesis occurs through a convergent pathway. A primary goal
was to synthesize 13C-labeled 15 with the label located at the guanidino carbon
and test whether the labeled material is incorporated into the streptolidine moiety
of STF (12a).
While there is strong evidence for the involvement of capreomycidine (17)
in the biosynthesis of the streptolidine moiety in STF, no intermediates have
beenidentified.Therefore,a second objective was toinvestigatethe
intermediacy of 17 in the formation of the streptolidine portion of 12a. Using cell-
free extracts (CFE) from S. 1-1689-23, [U-14C]arginine would be added and
radioactive compounds that are produced would be characterized.
An alternative method in determining the intermediacy of capreomycidine
(17) in the biosynthesis of streptolidine (15) would be through incorporation
studies using 13C-labeled 17.Based upon what has been published in the
literature, a more efficient synthesis of capreomycidine would need to be
designed and subsequently developed so that a 13C label could be placed at the
guanidino carbon of 17.This would provide labeled capreomycidine for use in
incorporation studies. Elucidation of this portion in the pathway could identify the
order of oxidations that occur in the conversion of arginine to 15.
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2283-2286.Chapter 2
The Intermediacy of Streptolidine in the Formation of Streptothricin F
Introduction
Several organisms have developed what can be identified as a convergent
biosynthesis for the formation of particular natural products.Convergent
biosynthesis is defined as a biosynthetic pathway in which the key structural
components of the molecule are made independently of each other, and then
coupled to form the core structure of the natural product.Post assembly
modifications such as methylations, acetylations, and oxidations or reductions
often occur before the molecule is presented in its biologically active form.
An example of a convergent pathway that has been extensively studied in
our laboratory pertains to the biosynthesis of blasticidin S (1). The identity of free
-arginine (3, Scheme 2.1) as a direct precursor to the -arginine moiety in I was
first reported by Gould in 1997,1 and later shown to be derived from a-arginine
(2).2The nucleoside cytosinine (28) was identified as an intermediate in the
biosynthesis of Iusing cell-free extracts (CFE) of S.griseochromogenes.3
Cytosinine is derived from D-glucose (23) and the nucleoside cytosine (29).
Cytosyl glucuronic acid (CGA, 30) is the only other compound identified as a true
intermediate in the formation of 28.Scheme 2.1. Proposed Pathway for the Biosynthesis of Blasticidin S (1) by S.
griseochromo genes
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The nikkomycins, isolated from Streptomyces tendae Tü901, are also
examples of peptidyl nucleoside antibiotics.Studies on the biosynthesis of the
nikkomycins have indicated that separate pathways synthesize the peptidyl and32
nucleoside moieties, which are then linked together by the formation of a peptide
bond (Scheme 2.2).6The primary biosynthetic precursors to the nucleoside
moiety in nikkomycin X (31) were identified as ribose (32), histidine (33) and
phosphoenolpyruvate (PEP).7'8 Fortheunusualaminoacid
hydroxypyridylhomothreonine (HPHT, 34), lysine (22) has been identified as the
primary precursor. All of the nikkomycin biosynthetic genes have been identified
from S.tendae Tü901and the first gene involved in HPHT formation was
shown to be a L-lysine 2-aminotransferase by Bruntner in1998.10More recently,
six additional genes were identified with HPHT biosynthesis, lending further
insight into the biosynthesis of the nikkomycins.Scheme 2.2. Partial Biosynthetic Scheme for Nikkomycin X; Convergence
of the Peptide and Nucleoside Pathways
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To determine whether streptothricin F (12a, cf. Scheme 1.15) is also
produced via a convergent biosynthesis, streptolidine (15) must first be identified
as a true intermediate. The intact incorporation of both-lysine (14)11 and D-
glucosamine (24)12 into streptothricin F (STF, 12a) has providedsupport for a
convergent biosynthesis of 12a. For additional support, labeled streptolidine (15)
was needed in order to gain insight into the biosynthesis of the nucleoside
portion of STF. It was desired that streptolidine havea "3C label at the guanidino34
carbon, to permit analysis of isolated STF by NMR spectroscopy.To obtain
labeled 15, a new synthesis could be developed, or a current synthesis be used
to incorporate the 13C label into the desired location. To date, two groups have
synthesized streptolidine. Independently,Goto13andKusumoto14have
reported the synthesis of 15 using ribose derivatives that showed stereochemical
resemblance to that of streptolidine (32, Scheme 2.3).The ribose derivatives
used in Goto's and Kusumoto's synthesis were first reported by Hildesheim et al.
in 1969.15
Scheme 2.3. Synthesis of Ribose Derivative 39 with Stereochemistry
Related to Streptolidine(j5)19
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In Goto's synthesis ofstreptolidine,13diazide 36 (Scheme 2.4) was
reduced and the resulting aziridine protected as the diacetate (40) in moderate
yield.Nucleophilic opening of the aziridine using sodium azide afforded35
monoazide 41 which was subsequently reduced and protected as the triacetate,
42. Because conversion of the acetal (42) to the corresponding hemiacetal (43)
under acidic conditions resulted in partial cleavage of the amides in 42/43, 42
was first converted to tetraacetate 44 followed by saponification to generate 43.
Oxidation of hemiacetal 43 to the lactone (45) was achieved in poor yield.
Deprotection of the amines to generate triamine 46, followed by reaction with
cyanogen bromide to form the guanidino heterocycle, afforded 15 in moderate
yield.
Scheme 2.4. Goto's Synthesis of Streptolidine (15) via Diazide3617
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Kusumoto's synthesis of streptolidine (15) is nearly identical to Goto's,
with the exception that the benzyloxycarbonyl (Cbz) protecting group was used
(Scheme 2.5).14Beginning with diazide 36, reduction using lithium aluminum
hydride followed by protection of the resulting aziridine, providedintermediate
47. Nucleophilicringopeningoftheaziridinewithsodium azidein
dimethylformamide produced the desired monoazide (48) in reasonable yield.
Conversion of 48 to the corresponding triamine via catalytic reduction and
protection of the resulting triamine afforded the desired Cbz-protected triamine
(49).Hydrolysis of 49 to hemiacetal 50, followed by oxidation using chromium
trioxide,yielded lactone 51 which was then deprotected to triamine 46.
Cyclization using cyanogen bromide afforded 15, albeit in low yield.Scheme 2.5.Kusumoto's Synthesis of Streptolidine(15)via
36Using Benzyloxycarbonyl ProtectingGroups18
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In an attempt to obtain49without going through an aziridine intermediate,
Kusumoto later reported on the formation of40using D-xylose(52)as the
starting sugar (Scheme2.6).16In this synthesis,52was first treated withHCIin
methanol followed by mesyl chloride in pyridine to afford acetals53aand53b,
predominately as the 13-anomer(53).Reactionof 53with sodium azide produced
the corresponding diazides54aand54bas well as a very small amount(0.75%
yield) of triazide55.Because methyl 13-furanosides do not readily undergo
displacement reactions atC-2, 54bwas converted to the a-anomer(54a)bybubbling dry hydrochloric acid into a solutionof 54bin methanol. Acetal54awas
obtained in16%yield with the recoveryof 64% 54b.The a-diazide was
converted to the corresponding triazide55,which was subsequently reduced and
protected to give acetal49.Hydrolysisof 49afforded hemiacetal50,which could
be converted to15in three steps.
Scheme 2.6.Kusumoto's SynthesisofIntermediate50via D-Xylose
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Results and Discussion
Synthesis of fguanidine-13CJStrepto!idine
When synthesizing isotopically labeled molecules with either stable or
radioisotopes, it is important to place the label in an appropriate intermediate in
the synthetic scheme.Labeled compounds are very expensive. To minimize
cost, the incorporation of the label into the target compound needs to be toward
the end of the synthesis. Also of consideration when working with radiolabels is
disposal cost of waste material from the individual reactions. For our synthesis of
labeled streptolidine, it was decided to use Kusumoto's synthetic route. By using
13C-labeled cyanogen bromide, the chemical label could be introduced at the end
of the synthesis. While many of the synthetic steps in the Kusumoto synthesis
were low in yield, unreacted starting material obtained in several of the reactions,
could be recycled to increase the overall yield of certain synthetic steps.Goto's
synthesis reported no isolation of unreacted starting material in any of the
reaction sequences. Furthermore, the use of the Cbz-protecting group over the
acetyl group had the additional advantage of being UV-active, making it easier to
follow during the course of the synthesis. The most direct route to 15 appeared
to be from the use of D-ribose (32) as the starting material, instead of D-xylose
(52).
Following Kusumoto's synthesis of streptolidine (15) from D-ribose,
hemiacetal 50 was synthesized without difficulty.At this stage, alternative
oxidation chemistry was attempted in hopes of increasing the yield. Among the
oxidative reagents tested were Dess-Martin'speriodininane17and tetra-n-
propylammonium perruthenate(TPAP).18These reagents, however, resulted in
either little or no lactone 51.It was discovered that hemiacetal 50 was insoluble
or sparingly soluble in most organic solvents, including methylene chloride,40
chloroform, acetonitrile, and tetrahydrofuran, which may explain the poor yield in
the oxidation of 50 to 51.
We also attempted to improve the addition of cyanogen bromide to
triamine 46.Initially, it was noted that the pH of the reaction solution gradually
dropped from pH 11to pH6.5and correlated with very poor yields of
streptolidine.Because the pKa of a typical primary amine is between8.5and
9.0,19it was speculated that as the amines reacted with the cyanogen bromide,
the resulting HBr generated would protonate the remaining amine, thus making it
non-nucleophilic.Indeed, when the pH of the reaction mixture was maintained
between9.5and10.5,higher yields of 15 (up to85%)were obtained (Scheme
2.7).This simple procedural modification was used inthe synthesis of
[guanidino-'3C]streptolidine (56) with greater than98%'3C enrichment in the
guanidino carbon, based upon Fast Atom Bombardment Mass Spectrometry
(FABMS). The '3C NMR of labeled 56 clearly showed1.9%enrichment at the
guanidino carbon of streptolidine (Figure 2.1) when compared to the natural
abundance spectrum of 12a.
Scheme 2.7. Preparation of [guanidino-13C]Streptolidine from Triamine 46
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Figure 2.1. 13C NMR Spectrum of [guanid/no-13C}Streptolidine42
Incorporation Studies Using fguanidino-13CJStreptolidine
Incorporation studies were performedinchemically defined O'Brein
medium with slight modifications.The [guanidino-13C]streptolidine (61) thus
synthesized was introduced to production flasks of S. L-1689-23 in one pulse,
twelve hours after inoculation.
The labeled streptothricin F that was produced was isolated (18 mg) using
the reportedprocedure.2°Based upon the intensity of the signal for C-6 (160
ppm) in the carbonyl region of the 13C NMR spectra of both the control and
labeled STF, a 1.9% enrichment of the guanidino resonance at 160 ppm was
observed (Figure 2.2).
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Figure 2.2. Partial '3C NMR Spectra ofA)STF Control and B) [guanidino-13C]-
STF From Incorporation Study43
The clear enrichment of the guanidino carbon in the streptolidine moiety of
streptothricin F (12a) confirms it as a free intermediate and provides further
evidence for a convergent biosynthesis.It remains to be determined when, in the
biosynthesis of 15, formation of the secondary alcohol occurs. One possibility,
as shown in Scheme 2.8, is after the initial formation of dehydroxystreptolidine
(57). An alternative is the hydroxylation of arginine to form J-hydroxyarginine,
58, which could then undergo the oxidative cyclization to form capreomycidine
derivative 59. The third possibility is the oxidation of capreomycidine (17) to form
59, which then undergoes rearrangement to 15. Also yet to be addressed is the
timing of amide bond formation in the streptolidine moiety of STF.
Scheme 2.8. Alternate Biosynthetic Routes to Streptolidine (15)
H2Ny
H2NCO2H
2
[0]
H
HN) HN<J,OH
H2NyN
I
H2NCO2H
H H
62
[0]
[0]
H2NCO2H
64
J
I44
Sum ma rv
[guanidino-13C]Streptolidine was synthesized and added to production
flasks of Streptomyces Iavendulae L-1 689-23. The resulting streptothricin F was
purified and analyzed by both 13C NMR and FABMS. From the 13C NMR of the
STF isolated, a 1.9% enhancement of the guanidino signal was calculated. This
resultclearlydemonstratesthatstreptolidineisanintermediateinthe
biosynthesis of streptothricin F, and lends further support for a convergent
biosynthesis.
Experimental
Genera!
Streptomyces L-1689-23 used in the present studies was the same
enhanced antibiotic producer used in prior biosynthetic studies by the Gould
group.Bacillus subtilis ATCC 6633 spore suspension was obtained from
Baltimore Biological Laboratories (Cockeysville, MD).Bacto agar, brain-heart
infusionagar,yeastextract,andtryptose were purchased fromDifco
Laboratories (Detroit, Ml).Beef extract was purchased from Sigma Chemical
Company (St. Louis, MO). Commerical molasses and cornstarch was used.
All fermentation media were prepared with double-deionized water (Milli-
Q, Millipore).Sterilization of media for use in the biosynthetic studies was
performed in an AMSCO general-purpose steam powered sterilizer operating at
121 °C.Fermentation studies were carried out in a Lab-Line model 3595
gyrotatory incubator shaker having a one-inch throw and operating at 29 °C and
225 rpm. Incubations for bioassay and in the preparation of slants for short-term
maintenance were done in VWR model 1520 incubators.All sterile procedures45
were performed in anEdgeGARDTMhood manufactured by The Baker Company,
Inc. (Sanford, ME). The paper disks used for bioassay (#740-E) were purchased
from Schleicher and Schuell (Keene, NH). Ion exchange resins and LH-20 resin
were purchased from Sigma Chemical Company (St. Louis, MO).
Sodium cyanide (99.99% 13C enriched) was purchased from Cambridge
Isotope Laboratories (Cambridge, MA). All other chemicals were purchased from
Aldrich or Sigma Chemical Company and used without further purification.
Anhydrous THF was obtained by refluxing over sodium metal in the presence of
benzophenone.Anhydrous dimethylformamide (DMF) was obtained by first
letting 500 mL stand over 4Amolecular sieves for 24 hours. The DMF was then
distilled under argon into a receiving vessel containing additional 4Amolecular
sieves. The DMF was stored under argon and used without further purification.
NMR spectra were reported on either a Bruker AM 400 or AC 300
spectrometer, where noted. Pyridine or was added as an internal chemical shift
reference (135.5 for 13C, middle resonance for pyridine) when spectra were
recorded in D20.Mass spectra were obtained with a Kratos MS 50 IC
spectrometer.Infrared spectra were recorded on a Nicolet 5DXB FT-IR
spectrophotometer.
Maintenance of S. Iavendulae
S. Iavendulae was maintained on yeast-malt extract agar slants, stored at
4 °C.Original slants were prepared using S. Iavendu!ae spores stored on agar
plugs in liquid nitrogen (-196 °C).For the generation of new slants, one agar
plug was transferred into 50 mL of YME medium (consisting of 0.4% yeast
extract, 1.0% malt extract, and 0.4% glucose dissolved in Milli-Q water, adjusted
to pH 7.3 with I M KOH prior to sterilization) and this was incubated in a shaker
at 29 °C and 225 rpm for 48 h. A portion of the resulting growth (0.1 mL per
slant) was used to inoculate YME agar slants (15 mL, consisting of 0.4% yeast46
extract, 1.0% malt extract, 0.4% glucose, and 2% Bacto agar in Milli-Q water,
adjusted to pH 7.3 with 1 M KOH prior to sterilization), which were then incubated
at 29 °C for seven days.After this time period, the slants showed dense
pink/brown growth and were stored at 4 °C. New slants were prepared every
nine months.
Seed and Production Medium
Seed medium was composed of 0.3% beef extract, 0.5% tryptose, 0.5%
yeast extract, 0.1% glucose and 2.4% cornstarch in Milli-Q water.A seed
medium of 100 mL was inoculated with 1cm2of sporulated growth from a
recently prepared slant using a sterile inoculating loop.The inoculated seed
medium was incubated for 64 hrs at 29 °C and 225 rpm in a rotary shaker.
Production broth was prepared by inoculating with 8.0% (v/v) of the above
seed culture to a chemically defined medium prepared in the following manner:
Glycine (2.6 g), potassium phosphate-dibasic (0.2 g), and sodium acetate (1.36
g) were dissolved in I L Milli-Q water and to this was added 2 mL of 250 mL
stock solutions containing magnesium sulfate-heptahydrate (31.22 g) and
manganese sulfate-monohydrate (0.557 g), copper sulfate-pentahydrate (0.998
g) and zinc sulfate-heptahydrate (1.87 g) calcium chloride-dihydrate (4.14 g), and
ferrous sulfate-heptahydrate (1.56 g). The solutions were autoclaved, and after
cooling to room temperature, sterilized calcium carbonate (10 g) was added. A
solution of glycerol (20 g) and glucose (2.5 g) in 20 mL MilIi-Q water was then
introduced via a sterile filter.Upon inoculation of the production medium, the
flasks were incubated at 29 °C and 225 rpm for 48 hrs.47
Streptothric!n F Bioassay
The concentration of streptothricin F was determined by correlating the
diameter of the zone of inhibition of growth of Bacillus subtilis on brain-heart
infusion agar plates. A B. subtilis spore suspension was diluted 50-fold with
0.3% saline in 0.01% Tween 80 solution for bioassay use. To a bioassay plate
(2OmL brain-heart infusion agar/plate) was added 100 tL of the diluted spore
suspension and spread evenly over the surface of the plate.Paper bioassay
disks were evenly spaced on the surface of the plate (up to 4 disks per plate),
and 50 j.iL of the sample to be tested was applied to each disk. The plates were
incubated for fifteen hours at 35 °C, and then the diameter of the zone of
inhibition was measured and correlated to a standard curve. The standard curve
was prepared using known concentrations of streptothricin F.
Radial TLC of Streptothricin F
The radial TLC system used for the detection of STF (12a) was developed
byMartinkus.21The apparatus consists of the bottom of a glass petrie dish,
which is used as the solvent reservoir, and a glass plate with a 1.5 mm hole
drilled into the center. A small diameter tube is inserted into the hole in the plate.
The solvent (Pyridine/water/l-PrOH/AcOH, 15:12:5:3) is delivered, via capillary
action, to the center of a 10 x 10 cm TLC plate (Whatmann aluminum-backed
silica gel 60).Streptothricin F(Rf0.46) was detected using 0.2% ethanolic
ninhydrin spray.Synthesis of (g uan idi no-13CjStreptolidine
Methyl 2,3, 5-tr!tosyl-fl-D-ribofuranos!de (35)
To a solution of D-ribose (32, 10.0 g, 66.7 mmol) in MeOH (200 mL) at 0
°C was added I mL of concentrated H2SO4 and the reaction stirred at 4 °C
overnight (approx. 16 hrs).The solution was neutralized with amberlite IR-45
(OH form, 300-400 mesh) and the solvent removed to afford crude methyl f3-D-
ribose as colorless syrup (11.2 g).The crude syrup was dissolved in pyridine
(150 mL) and p-toluenesulfonyl chloride (43.8 g, 0.23 mol) added with stirring.
Upon completion of the addition, the solution was stirred at room temperature for
40 hrs. The reaction was terminated by the addition of water (100 mL) followed
by extraction with CH2Cl2 (3 x 200 mL).The combined organic layers were
washed with aqueous HCI (10% conc. HCI, 3 x 200 mL), sat. NaHCO3 (3 x 200
mL), brine (1 x 200 mL) and then dried over Na2SO4. Filtration and evaporation
of the solvent afforded a dark yellow residue (22.9 g).This residue was
recrystallized from CHCI3/Hexane to provide the tritosyl derivative as a light
yellow solid (20.4 g, 68%). A NMR quality sample was obtained by purifying 100
mg of the material by flash chromatography (hexanes/EtOAc, 3:1, 2 x 15 cm
column, detection: UV).[aI529.0° (c 0.87, CHCI3); IR (KBr) 1599, 1379, 1189
cm1;1H NMR (400 MHz, CDCI3, 25 °C) 6 (ppm) 2.45 (s, 3H), 2.46 (s, 6H), 3.82
(dd, J = 4.5 and 11 Hz, I H), 4.02 (dd, J = 2.9 and 11 Hz, I H), 4.22 (m, I H), 4.65
(d, J = 4.6 Hz, I H), 4.83 (dd, J = 4.6 and 7.4 Hz, I H), 4.90 (s, 1 H), 7.35 (t, J =8.3
Hz, 6H), 7.67 (d, J = 8.2 Hz, 2H), 7.73 (d, J = 8.2 Hz, 2H), 7.79 (d, J = 8.2 Hz,
2H); 13C NMR (100 MHz, CDCI3, 25 °C) 6 (ppm) 21.85, 21.93, 21.96, 55.51,
67.85, 74.67, 77.42, 79.27, 105.4, 128.2, 128.3, 128.4, 130.1, 130.2, 130.4,
132.1, 132.9, 145.3, 145.7, 146.1.49
Methyl 3, 5-diazido-2-tosyl-f3-D-xylofuranoside (36)
To the tritosyl derivative 35 (20.4 g, 0.033 mol) in DMF (250 mL) was
added sodium azide (7.28 g, 0.11 mol) and the mixture heated at 145 °C for 2.5
hrs.After cooling to room temperature, the mixture was filtered through celite
and the solvent removed in vacuo. The syrup that was obtained was dissolved in
150 mL of hot MeOH and allowed to cool to room temperature. The crystals
(monoazide, 7.8 g, 45%) were filtered off and the mother liquor evaporated in
vacuo.The resultingdark orangeoil(8.2g) waspurifiedby flash
chromatography (hexanes/EtOAc, 4:1, 6 x 20 cm column, detection: UV)
affording the desired product (4.3 g, 35%) as oil.The monoazide can be
converted to the diazide using the same conditions as above.Monoazide:
[a5 79 3°(lit.18[a580.5°) (c 1.36, CHCI3); IR (KBr) 2104, 1598, 1366 cm'; 'H
NMR (400 MHz, CDCI3, 25 °C) 6 (ppm) 2.46 (s, 3H), 2.47 (s, 3H), 3.05 (dd, J =
4.7 and 13Hz, IH), 3.35(s, 3H), 3.41 (dd, J= 2.9 and 13Hz, 1H), 4.22 (m, IH),
4.69 (d, J = 4.6 Hz, I H), 4.84 (dd, J4.7 and 7.8 Hz, 1 H), 4.96 (s, 1 H), 7.36 (t, J
= 8.7 Hz, 4H), 7.70 (d, J = 8.3 Hz, 2H), 7.82 (d, J = 8.3 Hz, 2H); '3C NMR (100
MHz, CDCI3, 25 °C) 6 42.1, 42.2, 42.7, 57.0, 66.8, 68.6, 74.9, 102.6, 128.1,
128.2, 128.4, 128.5, 128.6, 135.4, 136.5, 156.5, 161.5. Diazide 36: [aI5-53.9° (c
2.86, Et20); lR (neat) 2108, 1597, 1379 cm'; 1H NMR (300 MHz, CDCI3, 25 °C) 6
2.48 (s, 3H), 3.32 (s, 3H), 3.36 (dd, J = 5.3 and 13 Hz, I H), 3.49 (dd, J = 7.5 and
12.8 Hz, IH), 4.18 (dd, J= 2.6 and 6.3 Hz, IH), 4.40 (m, IH), 4.77 (m, IH), 4.86
(s, IH), 7.41 (d, J = 8.3 Hz, 2H), 7.84 (d, J = 8.5 Hz, 2H); '3C NMR (75.5 MHz,
CDCI3, 25 °C) 6 (ppm) 21.6, 51.7, 55.9, 64.9, 79.4, 86.2, 106.8, 128.1, 130.3,
132.4, 146.0; MS (Cl): m/z 367.0 (M- 1); HRMS (Cl): calcd for C13H15N605S
367.0825, obsd 367.0822.50
Methyl 5-benzviox ycarbamido-2I3-benzyloxycarbonyl-azido-2, 3,5-
trideoxy-fl-D-lyxofuranoside (47)
To a suspension of lithium aluminum hydride (2.12 g, 54 mmol) in dry THE
(20 mL) at 0 °C was slowly added a solution of the diazide 36 (4.3g, 11.2 mmol)
in dry THE (25 mL) via cannula. The reaction mixture was stirred at 0 °C for 1.5
hrs and then refluxed for an additional 2 hrs. After cooling to room temperature,
the excess lithium aluminum hydride was destroyed by the slow addition of
saturatedNa2SO4at 0 °C. The aluminum salts were filtered off and washed with
EtOH (3 x 100 mL) and Et20 (3 x 100 mL). The washings were combined and
the solvents removed in vacuo. The resulting light yellow residue was dissolved
in 100 mL of EtOH and cooled to 0 °C. To the ice-cold solution was added Et3N
(3.9 mL, 28 mmol) followed by the slow addition of benzyl chloroformate (4.0 mL,
28 mmol) over 30 mm. The mixture was stirred at 0 °C for 0.5 hours followed by
2.5 hrs at room temperature. Water (150 mL) was then added and the resulting
white crystals were filtered off and dried to afford 3.1 g (69%) of the desired
product.[cx5-93.1° (c 0.8, CHCI3); IR (KBr) 3311, 1717, 1694, 1552cm1;1H
NMR (300 MHz, CDCI3, 25 °C) ö (ppm) 3.24 (dd, J = 1.8 and 4.9 Hz, I H), 3.35
(dd, J = 1.0 and 5.0 Hz) 3.46 (m, I H), 3.49 (s, 3H), 3.61 (m, I H), 4.05 (t, J = 4.6
Hz, IH), 4.96 (d, J = 1.0 Hz, IH), 5.10 (m, 4H), 5.34 (t, J = 5.0 Hz, IH) 7.32 (s,
5H), 7.33 (s, 5H); 13C NMR (75.5 MHz, CDCI3, 25 °C) 6 (ppm) 42.0, 42.2, 42.7,
57.1, 66.8, 68.6, 75.0, 102.6, 128.1, 128.2, 128.4, 128.5, 128.6, 135.4, 136.5,
156.5, 161.5; MS (Cl): m/z 412.2 (M); HRMS (Cl): calcd forC22H24N206
412.1634, obsd 412.1632.51
Methyl 3-azido-2,5-dibenzyloxycarbamido-2, 3, 5-trideoxy-fl-D-
arabionfuranoside (48)
To a solution of the Cbz-protected aziridine 47 (3.1 g, 7.5 mmol) in 50 mL
anhydrous DMF was added sodium azide (2.4 g, 37.5 mmol) and the mixture
stirred at 90 °C for 1 hour under argon atmosphere. After cooling, the excess
sodium azide was filtered off and the solvent removed in vacuo. The resulting
residue was purified by flash chromatography (hexanes/EtOAc, 2:1, 4 x 18 cm
column, detection: UV) to afford 1.6 g (47%) of the desired product as a white
solid. A total of 1.1 g of the undesired 2-azido isomer (48b) was also obtained.
(48a) [aj5-26.8° (c 2.20, EtOAc); IR (KBr) 3326 (br), 2110, 1693 (br)cm1;1H
NMR (400 MHz, CDCI3, 25 °C) ö (ppm) 3.39 (s, 3H), 3.45 (m, 2H), 3.69 (t, J = 8.8
Hz, IH), 3.90 (dd, J = 4.6 and 12.4 Hz), 4.35 (ddd, J = 4.8 and 10.0 Hz, 1H), 4.78
(d, J = 4.6 Hz, IH), 5.00 (bs, IH), 5.16 (m, 5H), 7.34 (m, IOH); 13C NMR (100
MHz, CDCI3, 25 °C)(ppm) 43.8, 55.5, 58.9, 65.5, 67.1, 67.4, 80.2, 101.6,
128.4, 128.5, 128.6, 128.7, 136.2, 136.5, 155.9, 156.8; MS (FAB): m/z456.2 (M
+ 1); HRMS (FAB): calcd for C22H26N506 456.1883, obsd 456.1891. (48b)[aI5
-25.2° (c 1.85, EtOAc); IR (KBr) 3328 (br), 2109, 1696 (br)cm1;1H NMR (400
MHz, CDCI3, 25 °C)(ppm) 7.36 (m, 1OH), 5.66 (bd, J = 9.5 Hz, IH), 5.25 (bs,
IH), 5.12 (m, 4H), 4.83 (s, IH), 4.40 (m, IH), 4.33 (dd, J= 6.0 and 11.5 Hz, IH),
3.86 (S, IH), 3.56 (m, IH), 3.37 (s, 3H), 3.26 (m, IH); 13C NMR (100 MHz,
CDCI3, 25 °C)(ppm) 156.6, 156.0, 136.0, 128.8, 128.6, 127.7, 106.7, 80.6,
69.7, 67.6, 67.0, 55.7, 41.5; MS (FAB): m/z 456.2 (M + 1); HRMS (FAB): calcd
for C22H26N506 456.1883, obsd 456.1891.52
Methyl 2,3, 5-tn benz yloxycarbam!do-2 ,3 5-tnideoxy-13-D-
anabinofuranoside (49)
To a solution of the monoazide 48 (1.6 g, 3.5 mmol) and conG. HCI (1.05
mL) in 40 mL MeOH was added Pd/C (10%, 168 mg) and the resulting mixture
stirred at room temperature under hydrogen atmosphere overnight. The catalyst
was then filtered off and an additional 50 mL MeOH was added. To the solution
was added triethylamine (2.4 mL, 17.5 mmol), the mixture was cooled to 0 °C,
and then benzyl chloroformate (2.5 mL 17.5 mmol) added slowly over 30 minutes
followed by stirring at room temperature for an additional 1 hour. Water (50 mL)
was then added and the white precipitate was filtered off to afford 1.15 g (58%) of
the desired product as a white solid.[a5-17.9° (c 2.01, CHCI3); IR (KBr) 3409
(br), 1699 (br)cm1;1H NMR (300 MHz, CDCI3, 25 °C) ö (ppm) 7.32 (m, 15H,
5.50 (bd, I H), 5.32 (bd, 1 H), 5.07 (m, 6H), 4.76 (d, J = 4.1 Hz, 1 H), 4.23 (m, I H),
3.91 (m, 2H), 3.53 (m, IH), 3.39 (m, IH), 3.31 (s, 3H), 3.08 (m, 2H); '3C NMR (75
MHz, CDCI3, 25 °C)(ppm) 157.2, 156.7, 136.9, 136.2, 128.8, 128.7, 128.6,
128.5, 128.4, 128.3, 128.2, 100.8, 81.6, 77.4, 67.5, 67.4, 66.8, 58.0, 55.3, 46.0,
44.5; MS (FAB): m/z 550.2 (M + 1); HRMS (FAB): calcd for C29H32N308
549.2111, obsd 549.2118.
2,3, 5-Tn benzyloxycarbamido-2,3, 5-tnideoxv-D-arabinofuranoside (50)
To a solution of the acetal 49 (1.15 g, 2.1 mmol) in 50 mL dioxane was
added 50 mL of 2 M p-toluenesulfonic acid and the mixture heated under reflux
for 2 hrs. The mixture was concentrated in vacuo to one-half the original volume
and extracted with CH2Cl2 (3 x 100 mL). The combined organic layers were
washed with sat. NaHCO3 (3 x 100 mL), brine (1 x 100 mL), and dried over
sodium sulfate.Filtration and removal of the solvent afforded a yellow residue
which was purified by flash chromatography (CH2Cl2/EtOAc, 2:1, 4 x 18 cm53
column, detection: UV) to obtain the desired hemiacetal (425 mg, 39%) as well
as 400 mg of recovered starting material.[aj5-19.2° (c 1.98, 1,4-dioxane); IR
(neat) 3504 (br), 1694 (br)cm1;1H NMR (300 MHz, CDCI3, 25 °C)(ppm) 7.34
(m, 15H), 5.60 (m, 2H), 5.34 (d, J = 8.0 Hz, IH), 5.09 (m, 6H), 4.78 (d, J = 4.5
Hz, I H), 4.24 (ddd, J = 4.5, 4.5 and 4.7 Hz, I H), 3.90 (m, 2H), 3.58 (ddd, J = 3.4,
4.8 and 5.8 Hz, IH), 3.39 (m, 4H); "3C NMR (75 MHz, CDCI3, 25 °C) ö (ppm)
157.2, 156.8, 136.9, 136.2, 128.8, 128.7, 128.5, 128.4, 128.2, 100.9, 81.6, 77.4,
67.5, 67.4, 66.8, 58.0, 55.3, 44.5; MS (FAB): m/z 536.2 (M + 1); HRMS (FAB):
calcd for C28H30N308 536.1955, obsd 536.1950.
2,3,5- Tribenzy!oxycarbamido-2,3, 5-trideoxy-D-arabino-1,4-Iactone
To a solution of the hemiacetal 50 (425 mg, 0.8 mmol) in acetic acid (35
mL) was added a drop of concdH2SO4and Cr03 (80 mg, 0.8 mmol) in
AcOH/H20 (4:1, 2 mL). The mixture was stirred at room temperature for 1.5 hrs,
then water (25 mL) was added and the mixture extracted with CH2Cl2 (3 x 50
mL). The combined organic layers were washed with sat. NaHCO3 (3 x 50 mL),
brine (1 x 50 mL) and dried over sodium sulfate.Filtration and removal of the
solventaffordedaresiduethat waspurifiedbyflashchromatography
(CH2Cl2/EtOAc, 2:1, 3 x 18 cm column, detection: UV) to give 210 mg (48%) of
the corresponding lactone. An additional 200 mg of recovered starting material
was also obtained.[a5-18.5° (c 1.88, 1,4-dioxane); IR (neat) 3321 (br), 1768
cm1;1H NMR (400 MHz, CDCI3, 25 °C)(ppm) 7.36 (m, 15H, 5.51 (bd, IH),
5.01 (m, 6H), 4.73 (d, J = 4.1 Hz, IH), 4.19 (m, IH), 4.01 (m, 2H),,3.35 (m, IH),
3.12 (m, 2H); 13C NMR (75 MHz, CDCI3, 25°C)7.11 (m, 15H), 7.01 (d, J = 8.7
Hz, 1 H), 5.41 (m, I H), 5.34 (m, 6H), 5.11 (d, J = 6.2 Hz, I H); 13C NMR (75 MHz,
CDCI3, 25 °C)(ppm) 172.0, 157.5, 157.4, 157.2, 127.6, 127.5, 127.4, 127.3,54
86.1, 70.2, 70.5, 69.9, 63.0, 49.5, ; MS (FAB): m/z 534.2 (M + 1); HRMS (FAB):
calcd for C28H28N308 534.1798, obsd 534.1796.
2,3,5- Triamino-2 ,3,5-trideoxy-D -arabino- 1,4-lactone (46)
To a solution of the protected triamine 51(210 mg, 0.4 mmol) in 5 mL
AcOH/HBr (sat. solution) was added anisole (0.15 mL) and the solution allowed
to stand at room temperature for 1.5 hours. Anhydrous ether (25 mL) was then
added and crystals of the deprotected triamine were filtered off to afford 120 mg
(77%) of the desired product as a white hygroscopic powder.[aj5-18.5° (c 1.87,
H20); lR (neat) 3415 (br), 1789cm1;1H NMR (300 MHz, MeOH-d4, 25 °C)
(ppm) 5.23 (m, 1H), 5.09 (d, J = 10 Hz, I H), 4.61 (m, IH), 3.81 (m, IH), 3.53
(m, 1H); '3C NMR (75 MHz, MeOH-d4, 25 °C) ö (ppm) 167.6, 68.1, 53.3, 52.7,
44.2; MS (FAB): m/z 146.1 (M + 1); HRMS (FAB): calcd for C5H12N302 146.0930,
obsd 146.0936.
fq uanid i no-13CJStreptoIid!ne (56)
The hydrobromide salt of the unprotected triamine 46(60 mg, 0.15 mmol)
was dissolved in 6 mL water and the pH was adjusted to 11.0 by the addition of
I M NaOH and then left to stand at room temperature for 2 hours. A solution of
Br13CN (85 mg, 0.8 mmol) in 3 mL water was added dropwise over 2.5 hours
while maintaining a pH of 10.5 11.0. The mixture was stirred for an additional
30 minutes and then evaporated to dryness. The residue was dissolved in 15 mL
of 6 M HCI and refluxed for 2 hours.Removal of the solvent afforded a dark
brown residue that was dissolved in a small amount of water and loaded onto an
Ag 50-X8 (NH4 form, 100-200 mesh, 1.5 x 20 cm) cation exchange column. The55
column was washed with water (400 mL) and then eluted with 0.2 M NH4OH.
Fractions of 10 mL were collected and ninhydrin positive fractions that contained
only streptolidine (as compared to standard) were pooled and the solvent
removed to afford 6 mg of the desired compound. 1H NMR (400 MHz, D20, 25
°C) ö(ppm) 4.45 (t, J = 4.3 Hz, IH), 4.23 (m, 2H), 3.38 (dd, J = 3.8 Hz and 9.1
Hz, I H), 3.26 (m, 1H); 13C NMR (100 MHz,CDCI3,25 °C)(ppm) 178.3, 160.3,
69.8, 63.7, 60.0, 42.3, ; MS (FAB): m/z 190.1 (M + 1); HRMS (FAB): calcd for
C513CH13N403190.1022, obsd 190.1011.
Incorporation Study Using (g uanidi no-13CJStreptolidine (56), First
Experiment
To each of two flaskscontaining 100 mL of chemically defined
fermentation medium were added 7 mg of [guanidino-13C}streptolidinein 2 mL
Milli-Q water via passage through a sterile filter.The addition of material was
performed twelve hours after inoculation. The production flasks were incubated
for an additional 32 hours.
After 48 hours from initial inoculation, the production broth was filtered
over celite. The production flasks and filter cake were washed with additional 50
mL Milli-Q water and the total volume recorded. A small sample was saved for
bioassay studies. The filtrate was passed through a column of Amberlite IRC-50
cation exchange resin (K form, 16-50 mesh, 1.5 x 19 cm column) at a flow rate
of 1.0 mL/min. Once all of the filtrate had been loaded onto the column, the
column was washed with Milli-Q water (100 mL). After collection of the effluent
and water wash as one large fraction, the volume was measured and a sample
saved for bioassay.The column was eluted with 0.3 M HCI, taking 10 mL
fractions at a flow rate of 1.0 mL/min. Ninhydrin-positive fractions were pooled,
the pH adjusted to 6.8 using 2% KOH, the volume measured, and an aliquot
saved for bioassay prior to lyophilization.56
The white powder resulting from freeze-drying (approx. 0.6 g) was
transferred to a 40 mL centrifuge tube and extracted with 10 mL portions of
methanol until the extracts were ninhydrin negative (typically 8 extractions were
necessary). After evaporation of the methanol, the material was dissolved in a
small amount of water and loaded onto a column of LH-20 gel filtration resin (1 x
30 cm column) with a flow rate of 1.0 mL/min. The column was washed with
water, collecting 3 mL fractions.Those fractions that were ninhydrin-positive
were analyzed by TLC (pyridine/H20/n-PrOH/AcOH, 15:12:5:3; detection: 0.2%
ninhydrin).Fractions containing only STF (Rt 0.46) were pooled and the pH
adjusted to 6.8 using 2% KOH prior to lyophilization. From this procedure, 18 mg
of STF was obtained, which was analyzed by '3C NMR.
Incorporation Study Using [guanidino-13CJStreptolidine (56), Second
Experiment
Using an additional 22 mg of [guanidino-13C]streptolidine, a second
incorporation study was performed as described previously. From a total of 200
mL of production medium was obtained 55 mg of antibiotic. The antibiotic was
analyzed by 13C NMR spectroscopy and a 2.2% enrichment of the guanidino
carbon of 12a was observed.
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Chapter 3
Testing the Intermediacy of Capreomycidine in the Biosynthesis of
Streptothricin F
Introduction
During the conversion of arginine (2) to the streptolidine moiety of
streptothricinF,atleast two separate oxidations are required.Inearly
speculation on the biogenesis of the streptolidine moiety in streptothricin F,
Bycroft and King proposed the intermediacy of capreomycidine (17) and arginine
(2, Scheme 3.1).1In their studies on streptolidine formation, Gould and co-
workers used 13C- and 15N-Iabeled arginine to support thishypothesis.2'3
Although capreomycidine had not been determined as an intermediate, several
experiments were designed to address this issue. One such experiment was an
incorporation study using labeled f-hydoxy-L-arginine.4While there was no
observable incorporation of f3-hydroxy-L-arginine into streptothricin F (12a), the
result does not exclude the intermediacy of such a compound.
Scheme 3.1. Biogenesis of the Streptolidine (15) Portion of
Streptothricin F From Arginine (2)
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17] 15Based upon the observed loss of deuterium labels at C-2 and C-3 of
arginine (cf. Scheme 1.1 O), the most likely explanation is in the intermediacy of
2-keto-L-arginine (19) which would have originated from the oxidation of 2-
hydroxy-L-arginine (18, Scheme 3.2). J3-Hydroxyarginine (19), however, was not
incorporatedintothestreptolidinemoiety of STF andisotopetrapping
experiments failed to confirm the intermediacy of 18.If these intermediates were
enzyme-bound, it could explain why no incorporation of labeled 19 was observed
in STF (12a) and why 18 was not isolated.If capreomycidine can be identified as
an intermediate, further experiments can be designed to address the conversion
of arginine into 17. To determine if 17 is synthesized in vitro from arginine, cell-
free extracts (CFE) of S. L-1689-23 would be generated and an assay developed
to test for enzyme activity related to the formation of 17.
Scheme 3.2. Proposed Oxidation Pathway to Capreomycidine (17)
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Examples of Hydroxylated Amino Acids
3-Hydroxyamino acids are very prevalent in nature and have been isolated
from a variety of sources.In the thesis of John Wityak, an extensive table of
naturally occurring-hydroxyamino acids has beencompiled,5and therefore, will
not be discussed in detail here. Surprisingly, there are no reports on the isolation
of-hydroxyarginine from any source. There are a few examples, however, of61
the isolation of both y-hydroxyarginine (57, Figure 3.1) and Nwhydroxyarginine
(58). With respect to y-hydroxyarginine, it has been identified as a constituent in
the antibiotic K-582, which is produced by the fungus Metarrhiziumanisopliae.6
Amino acid 57 is also a free amino acid found in lentil seed (Lens cu/mans
Med.),7and a constituent of polyphenolic proteins isolated from the adhesive
plaques of the marine mussel Mytilusedulis.8N°-Hydroxyarginine (58) is an
intermediate in the formation of nitric oxide in mammaliantissues9and is
synthesized from arginine via the enzyme nitric oxidesynthase.1°Neither 58 nor
nitric oxide synthase have ever been isolated from non-mammalian sources.
HNy HNL
H2NI¼1OH HO_NH(J
H2N1(OH
57 58
Figure 3.1. Hydroxylated Arginine Derivatives Found in Nature
Examples of Biological Oxidations
Many enzymes catalyze oxidations that are required in the formation of
primary and secondary natural products. One of the most abundant classes of
oxidases is the cytochrome P-450s and several cytochrome P-450-mediated
reactionshavebeenreportedfromStreptomycesspeciesandother
Actinomycetes.11Most bacterial cytochrome P-450s contain a heme-iron
complex and require NAD(P)H for activity.Cytochrome P-450 catalyzed
oxidations are initiated by binding of substrate (S), which occurs prior to binding
of oxygen (Scheme 3.3). Two reducing equivalents are sequentially transferred62
to the heme iron via a flavin nucleotide, ferredoxins, and/or cytochromeb5.
These reducing equivalents reduce one atom from molecular oxygen to water,
while the second oxygen atom is incorporated into the substrate.
Scheme 3.3. Proposed Catalytic Cycle of Cytochrome P-450
Monooxygenases
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The currently accepted mechanism by which cytochromes P-450 oxidize a
C-H bond is represented in Scheme3412Upon formation of the iron(IV) 0-
porphyrin radical complex, abstraction of a hydrogen atom occurs to form the
corresponding carbon radical. Transfer of hydroxy radical back to the substrate
completes the reaction.
Scheme 3.4. Proposed Mechanism for Cytochrome P.450 Mediated
Hydroxylation at a Saturated Carbon
P45OFe4-0 P450F
P450Fe3+ H0C
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Cytochromes P-450 catalyze the oxidation of activated and unactivated
carbon centers and are capable of catalyzing more than one reaction in a
biosynthetic sequence. The recombinant cytochrome P-450 DoxA, isolated from
Streptomyces sp. strain C5 has recently been shown to catalyze three distinct
reactions in the biosynthesis of doxorubicin; two separate hydroxylations, and
further oxidation of one of the hydroxy groups to aketone.13
A special class of monooxygenases has been characterized over the last
several years that contain an iron center, but are not heme proteins.These
enzymes typically require a-ketoglutarate and molecular oxygen for activity,
generating the oxidized substrate (product), carbon dioxide and succinate. One
example is clavaminate synthase (CAS). Clavaminate synthase catalyzes three
distinct reactions in the biosynthesis of the-lactamase inhibitor, clavulanic acid
(11, Scheme35)14Other examples of this class of monooxygenases include
IsoPenicillin N Synthase (IPNS), which catalyzes the oxidative cyclization of L-&
(a-Aminoadipoyl)-L-Cysteinyl-D-Valine (ACV, 59) to isopenicillin N (60),
15-17and
deacetoxycephalosporin C synthase (DAOCS), whichcatalyzesthering
expansion of penicillin N (61) to deacetoxycephalosporin C (62).'8Scheme 3.5. Examples of Non-Heme Monooxygenases Utilized in the
Biosynthesis of A) Clavulanic Acid, B) Isopenicillin N, and C)
Deacetoxycephalopsorin C
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Clavaminate synthase has been purified and characterized from S.
clavuligerus and shown to exist as two functional isozymes with 87% sequence
identity.19Clavaminate synthase has also been isolated from S.antibioticus.21
The genes that code for the two isozymes from S. clavuligerus have been cloned
and over-expressed in Escherichia co/i.22 Recently, the crystal structure of CAS
in complex with Fe(lI), ct-ketoglutarate, and the substrates N-a-acetyl-L-arginine
or proclavaminic acid has been reported and provided further insight into this
versatile monooxygenase.23 A generalized mechanism for the oxidation of a
substrate by CAS is shown in Scheme 3.6.
Scheme 3.6. Proposed Mechanism for the CAS CatalyticCycle23
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Because clavaminate synthase (CAS) oxidizes an arginine derivative at an
unactivated carbon center, the idea that an enzyme like CAS may be involved in
the biosynthesis of streptolidine (15) was very appealing.Reported enzyme
assay conditions using purified CAS can be modified to generate enzyme assaysfrom cell-free extracts of S. L-1689-23.Using [U-14C}arginine, the cell-free
extracts (CFE) can be probed for enzyme activity involved in the biosynthesis of
12a.This would be a simple method for assessing the intermediacy of
capreomycidine (17), as well as isolating potential biosynthetic intermediates, in
the formation of streptothricin F.
Results and Discussion
Generation of Cell-Free Extracts of S. L-1689-23 and Analysis of
Enzyme Activity Using a TLC Linear Analyzer
If a non-heme monooxygenase, similar to that of clavaminate synthase
(CAS) is involved in the oxidation of arginine (2) to streptolidine (15), an
established assay for CAS activitywouldhopefullypermit detectionof
intermediates in the biosynthesis of streptolidine/streptothricin F.The assay
conditions employed by Salowe etal.19and Lawlor etal.24are very
straightforward, and were employed in the generation of CFEs from S. L-1689-23
with only slight modifications.
Based upon STF production profiles, the onset of antibiotic biosynthesis
occurred at approximately twelve hours after initial inoculation of the production
medium. The mycelia from 12 hour-old production flasks were harvested via
centrifugation, re-suspended in buffer, and sonicated over ice.Removal of the
cellular debris by centrifugation afforded a crude extract.An aliquot of this
extract was incubated with iron (II) sulfate, dithiothreitol (DTT), sodium ascorbate,
a-ketoglutarate (a-KG), and arginine (containing 0.016 j.iCi[U-14C]arginine).
After termination of the assays, a sample (approximately 60 jiL) was initially
developed by radial thin-layer chromatography (TLC) as described in Chapter 2.
For the detection of radioactivity, the TLC plate was analyzed using a TLC-linear
analyzer. The initial results showed two separate radioactive compounds, one67
having an Rf of 0.75 and the other with an Rf of 0.50. Using [U-14C]arginine as a
standard, the high Rf component was identified as arginine. The other compound
had an Rf close to that of capreomycidine, which had also been used as a
standard. The low-Rf compound was absent from those assays that had been
boiled prior to the addition of substrate, cofactors, and incubation.This
demonstrated that the lOW-Rf compound was dependant upon active enzyme for
synthesis and suggested it was capreomycidine.
The quantitation of radioactivity in a given spot could not be determined
using the TLC-linear analyzer.Therefore,to determine the amount of
radioactivity present in each compound, the compound and silica support was
removed from the aluminum-backed TLC plate and analyzed by liquid scintillation
counting (LSC).Approximately 3000 dpm was found in the high Rf spot
(arginine, Table 3.1) and 1200 dpm in the low Rf spot (unknown).
Table 3.1. Conditions Used in Determining Initial
Enzyme Activity
Assay Number
component 2 3 4 5
DTT(lmM)
Na Ascorbate (1.5 mM)
FeSO4(45jiM)
a-KG(lmM)
a-KG (2 mM)
[U-14C]Arginine (1.0 mM)
Incubation Time 24 h24 h24 h24 h
Boiled Control V V
HighRfCompound (dpm x 100) 40 40 30 29
LowRfCompound (dpm x 100) 0 0 12 12In the next series of assays, the effect of increased a-KG upon the
formation of the low-Rf compound as well as incubation time was examined.
Table 3.2 lists the assay numbers and components/conditions used for each
assay.
Table 3.2. Conditions Used in Determining Dependency of a-Ketoglutarate
and Incubation Time on the Formation of the LOW-Rf Compound
Assay Number
Component 1 2 3 4 5 6 7 8
DTT(lmM) V V V V V V V V
Na Ascorbate (1.5 mM) V V V V V V V V
FeSO4(451.tM) V V V V V V V V
a-KG(lmM) V V V V V
u-KG(2mM) V V V
[U-14C]Arginine (1.0 mM) V V V V V V V V
Incubation Time 12h 24h 12h 24h 12h 24h 12h 24h
Boiled Control V V
LowRfCompound V V V V V V
Based upon the results from the TLC analysis, the lOW-Rf radioactive
compound was present in all of the assays. These results indicated that the
duration of the incubation did not affect the presence of the IOW-Rf compound in
the assays. Assays #5 and #6 (boiled controls) showed only the presence of
argin me.
Because the procedure used to grow S. L-1689-23 and generate the CFE
was time-consuming, the next set of experiments examined ways of cutting the
time needed to obtain a CFE while maintaining enzyme activity. To determine
whether CFE could be used from harvested cells that had been stored at 80 °C,
assays were conducted as represented in Table 3.2. CFE stored at either 4 °C
or 25 °C (Table 3.3, Assays 3-6) was also examined for enzyme activity.Table 3.3. Conditions Used in Determining Viability of CFE or
Harvested Cells at Various Temperatures
Assay Number
Component 1 2 3 4 5 6
DTT (1mM)
Na Ascorbate (1.5 mM)
FeSO4(45 j.tM)
a-KG (1mM)
CFE from Cells (-80 °C)
CFE stored at 4 °C
CFE stored at -25 °C
[U-14C]Arginine (1.0 mM)
Incubation Time
Boiled Control
Vt Vt Vt Vt Vt Vt
Vt Vt Vt Vt Vt Vt
Vt Vt Vt Vt Vt Vt
Vt Vt Vt Vt Vt Vt
Vt Vt
Vt Vt
Vt Vt
Vt Vt Vt Vt Vt Vt
12h12h12h 12h12h12h
Vt Vt Vt
LowRfCompound Vt
The results from the analysis of assays #4 and #6 showed no formation of
the Iow-Rf compound, while assay #2 contained the low-Rf compound, albeit in
smaller amounts than what had been observed using freshly harvested cells.
These results suggested that newly harvested mycelia should be used as the
source of the CFE
Inthelastseriesofassays,theeffectoftheironchelator
ethylenediaminetetraacetic acid (EDTA) upon addition to the assay, or the
absence of cofactors on the formation of the low Rf compound was examined.
EDTA was added to determine if the enzyme might contain a non-heme iron in
the active site. Table 3.4 lists the components and/or conditions used for each
assay.70
Table 3.4. Conditions Used in Determining Dependency of a-
Ketoglutarate or Addition of EDTA on the Formation of the
LOW-Rf Compound
Assay Number
Component 1 2 3 4 5 6 7 8
DIT (1mM)
Na Ascorbate (1.5 mM)
FeSO4(45 .tM)
a-KG (1 mM)
EDTA (4 mM)
EDTA (8 mM)
[U-14C]Arginine (1.0 mM)
Incubation Time
Boiled Control
VI VI VI VI VI VI VI
VI VI VI VI VI VI VI
VI VI VI VI VI
VI VI VI VI VI VI VI
VI
VI
VI VI VI VI VI VI VI VI
12h 12h12h12h12h 12h 12h 12h
LowR1Compound VI VI VI VI VI VI
When the assays were developed by radial TLC and analyzed, it was
observed that all of the assays, with the exception of assays #1 and #6,
contained the low Rf compound. In assays #7 and #8, where ferrous sulfate was
omitted and EDTA added, the amount of the low Rf compound appeared to be
much smaller (data not shown) than that present in the other assays. These
findings strongly suggested that the formation of the low R compound was
dependant upon the addition of a-KG to the assay. The observed decline in the
formation of the Rf compound upon addition of EDTA also suggested the
requirement of iron.
During the course of these experiments, it became apparent that the TLC
Linear Analyzer would be of limited use. The greatest problem being that the
amount of radioactivity that was contained within a spot on the TLC was difficult
to quantitate, let alone duplicate.Standards containing known amounts of [U-
14C]arginine were used in order to obtaina rough estimation as to the amount of
radioactivity that was in each radioactive compound present in the CFE. The71
standards themselves, however, were not consistent. Another problem was due
tto dynamic range. On several occasions, the amount of non-reacted arginine
was so large that it prevented any detection of the low Rf compound. Also of
concern was the degree of reproducibility with respect to the quantity of the
sample that was being applied to the TLC plate. While graduated micro-capillary
tubes were used to load samples onto the plates, the addition of sample was not
consistent.From these concerns,it was obvious that a better method of
detection and quantitation was required before the low Rf compound could be
identified.
Analysis of Enzyme Assays using High Performance Liquid
Chromatography
Because the low Rf compound in the enzyme assays was radioactive, it
must be derived from [U-14C]arginine.Initially, this unknown compound was to
be isolated and identified through isotope trapping experiments. This approach
however would not be the most efficient, in terms of time. An alternative method
would be to derivatize the components of the enzyme assay followed by analysis
using High Performance Liquid Chromatography (HPLC).This method had
several advantages over the use of the TLC Linear Analyzer.First of all,
dynamic range issues would be decreased.Secondly, the reproducibility
between samples would be better, and quantitation of compounds would be
easier.
There are several examples of the use of HPLC to isolate and qualitate
aminoacids.2528'29The types of amino acid derivatives used have included
(dimethylamino)azobenzenesulfonyl-(DABS),3°ortho-phthalaldehyde(OPA)
derivatives,31andI -dimethylaminonaphthalene-5-sulfonyl-(Dns,Dansyl)
derivatives,32with Dns-amino acids being the most popular.
It was decided to use the protocol reported by Tapuhi et al. for the
formation of Dns-amino acids and analysis by HPLC.32.The use of [U-72
14C}arginine was continued because, with the use of a radiochemical detector, it
would help in identifying compounds derived from arginine.
Conditions for the dansylation of amino acid standards and enzyme
assays were first developed. Over the course of establishing a procedure for the
derivitization of the enzyme assays, it was required to switch the initial sonication
buffer used in generating the CFE from Tris to potassium phosphate. Also, the
derivatization produced better results when 11 mM Dns-Cl was used. Once all of
the conditions were established, an enzyme assay containing all of the cofactors
was generated using CFE created from recently harvested mycelia. The assays
were terminated by the addition of cold methanol and then derivatized using
dansylchloride.An aliquotofthismixture was analyzedby HPLC.
Chromatograms from both the HPLC and radiochemical detector are presented
in Figure 3.2 and Figure 3.3.Based upon Dns-[U-14C]arginine used as a
standard, as well as a co-injection of Dns-arginine (Dns-Arg), the compound
having a retention time (tR) of 23.9 minutes was identified as Dns-Arg (data not
shown).Surprisingly,theassay containedthreeadditionalradioactive
compounds having retention times of 19.0, 22.9, and 34.2 minutes.These
compounds were not present in the boiled control, and were shown to be
produced in a time-dependent manner.Processing Method:DnsPMFineDetail
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Figure 3.2. HPLC Chromatogram of a Typical Enzyme Assay Containing all
Cofactors
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Figure 3.3.Radiochemical Chromatogram of a Typical Enzyme Assay
Containing all Cofactors74
It was observed that the compound having the retention time of 22.9
minutes had approximately the same tR as a standard of Dns-capreomycidine
(Dns-Cap).Using a new reverse-phase C-18 column from the same
manufacturer (Altech), a standard of Dns-Cap and the enzyme assaywas re-
analyzed to determine the extent that retention times had changed. Forsome
compounds, the retention times were dramatically different, especially for Dns-
Cap, which had changed from 22.9 to 30.0 minutes (Figure 3.4). Whena sample
of Dns-Cap was co-injected with the assay mixture, a clear increase in thearea
of the peak at 30 minutes was observed. However, very little radioactivity could
be detected for the compound at 30.0 minutes. To more accurately determine if
this compound contained any radioactivity, several injections of theassay were
performed, manually collecting the compound that eluted from the column attR =
30 minutes.Analysis of these combined fractions using a liquid scintillation
counter showed no radioactivity. Using unlabeled Dns-Arg, the compound at 30
minutes was collected in the same manner and submitted for analysis by FAB-
MS. No molecular ion with the same expected molecularmass as Dns-Cap were
observed.75
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Figure 3.4.HPLC Chromatograms of A) Dns-Capreomycidine Standard, B)
Dansylated Enzyme Assay Containing all Cofactors, C) Co-Injection of Enzyme
Assay with Dns-Capreomycidine, and D) the Radiochemical Chromatogram of
the Enzyme Assay76
A set of enzyme assays was generated to determine if any of the
radioactive components in the assay were dependent upon the cofactors added,
or upon the addition of EDTA (Table 3.5). Earlier results had suggested that the
low R compound was dependant upon ct-KG for its formation, while the addition
of EDTA also inhibited its formation.
Table 3.5. Conditions Used in Determining Dependency of Cofactors or
Addition of EDTA on the Formation of the LOW-Rf Compound by
HPLC
Assay Number
Component 1 2 3 4 5 6 7 8 9 10
DTT(lmM) /V/V V VVVV
Na Ascorbate (1.5 mM) V V VV V V VVV
FeSO4(45j.tM) V V V V V V V
a-KG(lmM) VV /V V V V V '
EDTA (4 mM) V
EDIA (8 mM) V
[U-14C]Arginine (1.0 mM) VV V V VVVV
Arginine (1.0 mM) VV
Incubationlime 12h 12h 12h12h12h12h 12h 12h 12h 12h
Boiled Control V V
tR = 19 mm cmpd (dpm x 100) 29 3120 2629222432
tR = 30 mm cmpd (dpm x 100) 6 8 7 9 6 8 6 5
tR=34mincmpd(dpmxl00) 13 17 16 21 151818 12
Analysis of the derivatized assays showed no effect from the absence of
any cofactors or upon the addition of EDTA. Only the boiled controls (assays #1
and #3) lacked the three unidentified compounds.
Lastly, the presence of cytochrome P-450 activity was examined in the
CFE. NADH or NADPH was added to CFE containing [U-14C]arginine (Table 3.6)
and the assays analyzed by HPLC. All of the assays tested contained only the77
three unidentified compounds, with the exception of the boiled controls (data not
shown).This suggested that the radioactive compounds derived from [U-
14C]arginine were not produced from cytochrome P-450 activity.
Table 3.6. Conditions Used in Determining Dependency of NADH or
NADPH on the Formation of the Unknown Radioactive
Compounds
Assay Number
component 1 2 3 4 5 6 7 8
NADH (2.0 mM)
NADPH (2.0 mM)
Arginine (1.0 mM)
[U-14C]Arginine (1.0 mM)
Incubation Time
Boiled Control
VI VI VI VI
VI VI
VI
VI VI VI VI
VI VI
VI VI
12h 12h 12h 12h 12h 12h 12h 12h
VI VI VI VI
tR = 19 mm cmpd (dpm x 100) 15 12 18 16
tR = 30 mm cmpd (dpm x 100) 5 8 6 6
tR=34mincmpd(dpmx 100) 10 8 15 14
Because it appeared that capreomycidine was not produced from cell-free
extracts of S. L-1689-23, it remained to be determined whether the two remaining
radioactive compounds at tR = 19 and 34 minutes were intermediates in the
biosynthesis of streptolidine.To identify these unknown compounds, Dns-
streptolidine (Dns-Str) and Dns--hydroxyarginine (Dns-Harg) were first analyzed
by HPLC to determine if these compounds had similar retention times to the
radioactive compounds of interest.Neither standard had similar retention times
(Dns-Str: tR = 26.6; Dns-Harg: tR = 21.2) and therefore suggested that the
unidentified compounds may be derived from arginine catabolism.iiI
In the catabolism of arginine, several species of bacteria, such as
Lactobacillussake,33Synergistesjonessi,34Halobacteriumsalinarium,35as well
as protazoa such as Trichomonasvagina/is36have been shown to contain
arginine deiminase, an enzyme that catalyzes the conversion of arginine (2) to
citrulline (63, Scheme 3.7). There are no reports of arginine deiminase activity
that has been described in Streptomyces.
Scheme 3.7. Arginine Catabolism to form Citrulline (63) and Ornithine (5)
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When Dns-Citrulline (Dns-Cit) was used as a standard, it was found to
have a nearly identical retention time to the unidentified compound at tR = 19
minutes (Figure 3.5).Co-injection of Dns-Cit with the enzyme assay mixture
resulted in an increase in the area of the peak corresponding to tR = 19 minutes.
Using unlabeled arginine as substrate, the desired compound was collected from
several injections of the assay and analyzed by positive FAB-MS, revealing a
molecular ion that matched the molecular ion of Dns-Cit. The same procedure
was used in identifying the compound having a retention time of 34 minutes
using DiDns-ornithine (DiDns-Orn) as the standard.As expected, both co-
injections (data not shown) and mass spectral data confirmed this compound to
be DiDns-Orn. Interestingly, when ornithine was added to enzyme assays prior
to the addition of substrate, the amount of citrulline produced by the CFE was
greatly decreased, suggesting an inhibitory role of ornithine for the enzyme that79
catalyzes the conversion of 2 to 63. Because ornithine is a known inhibitor of
arginine deiminase, this may be the first example of arginine deiminase activity
observed in the species Streptomyces.0.80-H
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Figure 3.5. HPLCChromatograms of A) Dns-Citrulline Standard, B) Dansylated
Enzyme Assay Containing all Cofactors, C) Co-injection of Enzyme
Assay with Dns-Citrulline, and D) the Radiochemical Chromatogram
of the Enzyme AssaySummary
Cell-free Extracts (CFE) of S. L-1 689-23 were generated to determine if
capreomycidine is synthesized in vitro.Development of the assays by radial
TLC and analysis using a TLC-Linear Analyzer, revealed the presence of two
radioactive compounds. Based upon the use of [U-14Cjarginine as a standard,
one of the compounds was identified as arginine. The other compound, which
contained a lowerRfthan arginine, had a similarRfto that of capreomycidine.
The presence of this compound within the enzyme assay was protein dependent
and appeared to be dependent upon the addition of a-ketoglutarate to the assay.
A High Performance Liquid Chromatography (HPLC) protocol was
developed for the isolation and identification of compounds derived from arginine.
A total of three unidentified compounds were present in initial assays.The
omission of cofactors or the addition of EDTA did not affect the production of
these compounds in the CFE. While one compound had an identical retention
time (tR) as that of capreomycidine, results obtained from this study suggested
that capreomycidine is not produced by CFE5 of S. L-1689-23.The two
remaining compounds were identified as citrulline and ornithine. Using ornithine
in the enzyme assays, the production of citrulline by the CFE was greatly
decreased, suggesting that the enzyme, a putative arginine deiminase,is
responsible for the conversion of arginine to citrulline.If arginine deiminase were
the active enzyme, this would be the first report of this activity in Streptomyces.Experimental
Genera!
Fermentation conditions and media preparation used in the following
experiments were described in Chapter 2.Analyses of radial TLC plates were
performed on a Tracemaster 20 Automatic TLC-Linear Analyzer (Berthold
Instruments, Berlin Germany). All enzyme assays were centrifuged using a
Brinkmann Eppendorf centrifuge model 5415C. Assays were concentrated using
a Savant Speedvac concentrator model SVCIOOH. All dansylated standards and
enzyme assays were analyzed using a Waters 600 multisolvent delivery system,
Hewlett Packard series 1050 autoinjector with a 200 pL injection loop, and a
Waters 996 photodiode array detector (256 nm detection). The entire system
was controlled using Millennium Chromatography Manager software (Waters
v.2.1). A Packard Radiomatic Flo-One Series A-500 radiochemical detector was
connected in series with the HPLC for the analysis of radioactive samples.
Cu!ture Maintenance and Fermentation Conditions
Standard culture maintenance and seed growth have been described in
Chapter 2.Chemically defined medium was used for the generation of all cell-
free studies. Fermentations were harvested at 12 or 24 hours after inoculation,
as noted.Preparation of Cell-free Extracts
Streptomyces Iavendulae L-1689-23 cells were grown in a chemically
defined medium and harvested at 12 hours after inoculation.The production
broth (typically 1000 mL) was transferred to 250 mL centrifuge bottles and the
mycelium was collected by centrifugation at 8,000 x g for 15 minutes at 4 °C.
The pellets were washed (1 L total volume) with sonication buffer (0.05 M MOPS
or Iris buffer, pH 7.0 at 4 °C) containing 0.1 mM DTT and then centrifuged at
8,000 x g for 15 minutes. The pellet was washed with 0.8 M sodium chloride
followed by 1.0 M potassium chloride and this procedure repeated twice. The
pellet obtained from the last potassium chloride washing was rinsed again with
the original sonication buffer and centrifuged at 8,000 x g for 15 minutes. The
pellets were combined and suspended in 50 mL of sonication buffer, cooled to 4
°C in an ice-water bath, and disrupted by sonication (Heat Systems Ultrasonic,
Inc. model W-225, large sonicationtip, power level8, 90% duty cycle).
Sonication consisted of three pulses twenty seconds long (ten bursts per pulse)
with one minute cooling intervals.
Enzyme Assay Conditions
For a typical assay, 1.0 mM arginine (100 .iL),1 mM DTT (25 l.LL), 1.5 mM
sodium ascorbate (25 j.tL),1 mM a-ketoglutarate (25 j.iL) and 45 RM ferrous
sulfate (25 jiL) in 50 mM assay buffer (MOPS, Tris, or Phosphate, pH 7.0) was
incubated with 300 j.tL CFE for a total volume of 500 jiL in 1.5 mL amber
centrifuge tubes.Incubations were performed for 12 hours in the dark at room
temperature (23-25 °C). The assays were terminated by the addition of cold (4
°C) ethanol and then centrifuged. For those analyses done using radial TLC, the
supernatant was used directly.For those analyses done using reverse phasechromatography, the supernatant was evaporated and the residue redissolved in
500 jiL Milli-Q water. For assays requiring [U-14C]arginine, 1 mM arginine stock
solution containing 3.49 x 104 dpm [U-14C]arginine per 100 j.tL was added.
Boiled controls were prepared by first placing 300 jiL of CFE into 1.5 mL amber
centrifuge tubes and submerging the tubes in boiling water for ten minutes.
Once cooled to room temperature, all appropriate cofactors and substrate was
added.
Analysis of Enzyme Assays Using a TLC Linear Analyzer
The radial TLC plates were prepared and developed as described in
Chapter 2. The TLC plates were analyzed for radioactivity using a TLC Linear
Analyzer (total measuring time: 360 minutes; Gain = 4; Y Resolution = 256; Start
scan (cm) = 10, Stop scan (cm)30; Step size (cm) = 0.4; Slit Width (cm) = 0.4;
Rf-Start-X (cm) = 0; Front-X (cm) = 20; Rf-Start-Y (cm) = 10; Front-Y (cm) = 30).
Synthesis of Dansyl-Amino Acids
To 2 mL of a 6 mM amino acid solution (buffered with 40 mMLi2CO3
buffer [adjusted to pH 9.5 using HCI]) was added a 11 mM solution of dansyl
chloride in acetonitrile and the resulting mixture was shaken lightly for one
minute. The reaction vial was then covered with aluminum foil and allowed to
stand at room temperature for one hour. The reaction was terminated by the
addition of 2% ethylamine hydrochloride solution and used without further
purification.Dansylation of Enzyme Assays
A total of 40 j.iL of the enzyme assay was transferred to a 1.5 mL amber
colored centrifuge tube (VWR Scientific) and to this was added 40 tL of a 80 mM
Li2CO3 buffer (pH 11.0) followed by the quick addition of 40 j.tL of 11 mM Dansyl
chloride in acetonitrile. The reaction mixture was vortexed quickly followed by
incubation in the dark at 35 °C for one hour. Reactions were terminated by the
addition of 2% ethylamine hydrochloride solution (4 iL).
Effect of a-Ketoglutarate Concentration on Enzyme Activity
Cell-free extracts of S. L-1 689-23 were prepared as described previously.
Enzyme assays containing either I pM or 2 j.tM a-ketoglutarate were incubated
at room temperature in the dark for 12 hours.Control experiments were
prepared in a similar manner using boiled CFE. The assays were terminated by
the addition of cold ethanol (500 pt) and then centrifuged. A total of 60 jiL of the
assay was spotted onto a 20 x 20 cm TLC plate and developed as previously
described.The TLC plates were then analyzed for radioactivity using a TLC
Linear Analyzer.
Assay for Enzyme Activity Using Stored Mycelia or Cell-Free Extracts
Enzyme assays containing the required cofactors and substrate were
incubated with 300 jtL of CFE generated from mycelia stored at 80 °C for two
weeks, CFE stored at 4 °C for one week, or CFE stored at 25 °C for one week
and incubated at room temperature in the dark for 12 hours. Control experiments
were prepared in a similar manner using boiled CFE. Assays were terminated bythe addition of cold ethanol (500 tL) and then centrifuged. A total of 60 pt of the
assay was spotted onto a 20 x 20 TLC plate and developed as previously
described.The TLC plates were then analyzed for radioactivity using a TLC
Linear Analyzer.
Effects of a-Ketoglutarate Omission orAddition of ED TA to Enzyme
Activity
Cell-free extracts of S. L-1 689-23 were prepared as described previously.
Sonication buffer (25j.iL) was added to enzyme assays lacking sodium
ascorbate, ferrous sulfate, dithiothreitol, or a-ketoglutarate so as to maintain a
final volume of 500 pt.Ferrous Sulfate was omitted from those assays in which
either 4 mM or 8 mM EDTA (50 j.iL) was added.All assays were incubated at
room temperature in the dark for 12 hours. Control experiments were prepared
in a similar manner using boiled CFE.The assays were terminated by the
addition of cold ethanol (500 .iL) and then centrifuged. A total of 60 jiL of the
assay was spotted onto a 20 x 20 TLC plate and developed as previously
described.The TLC plates were then analyzed for radioactivity using a TLC
Linear Analyzer. For the analysis of enzyme assays by HPLC, the supernatant
was evaporated to dryness and the residue dissolved in 500 mL Milli-Q water.
Samples were filtered though a 0.45 jim membrane filter before analysis.
Addition of NADH or NADPH to Cell-Free Extracts of S. L-1689-23
Cell-free extracts of S. L-1689-23 were prepared as described previously.
To freshly prepared cell-free extracts (300 jiL), 2.0 mM NADH or 2.0 mM NADPH
was added followed by the addition of substrate (100 jiL) for a final volume of500 j.tL.All assays were incubated at room temperature in the dark for 12 hours.
Control experiments were prepared in a similar manner using boiled CFE. The
assays were terminated by the addition of cold ethanol (500 jiL) and then
centrifuged.The supernatant was evaporated to dryness and the residue
dissolved in 500 mL Milli-Q water.Samples were filtered though a 0.45 jim
membrane filter before analysis.
Analysis of Enzyme Assays by High Performance Liquid
Chromatography
Dansylated standards or enzyme assays (75 j.tL, filtered before analysis)
were separated by gradient elution chromatography (0 to 100% solvent B in 30
minutes, curve 6), at a flow rate of 1.0 mL/min at 25 °C, using a 5 jim
EconosphereC18column (Alltech, 3.9 mm x 150 mm).An All-guard 5 jim
EconosphereC18guard column (Alltech) was placed between the injector and
column. At the end of the analysis, initial column conditions were restored using
a reverse gradient in ten minutes at a flow rate of 1.0 mL/min. A total of fifteen
minutes was then required for column equilibration.Solvent A consisted of 30
mM sodium phosphate buffer (pH 7.4) containing 5% methanol and 6.5%
tetrahydrofuran.Solvent B consisted of methanol and water (70:30 v/v).Both
mobile phases were filtered using Whatman 0.45 jim membrane filters and
degassed prior to use. For compound identification via co-injection, 75 jiL of the
appropriate standard was mixed with 75 j.tL of the assay and injected into the
HPLC (total volume = 150 j.tL).Identification of Dansyl-Citrulline in Cell-free Extracts of S. L-1689-23
Enzyme assays containing all required cofactors and substrate were
prepared and derivatized as described previously.For co-injections, 100 j.iL of
Dns-Citrulline was added to 100 jiL of dansylated enzyme assay containing [U-
14C]arginine and 150 tL was injected into the HPLC.For analysis by positive
FAB-MS, a total of 10 x 100 j.iL of dansylated assay, containing non-radioactive
substrate, was injected and the desired compound collected manually.The
solvent was removed in vacuo and submitted for mass-spectral analysis without
further purification.
Identification of Dansyl-Ornithine in Cell-free Extracts of S. L-1689-23
Enzyme assays containing all required cofactors and substrate were
prepared and derivatized as described previously.For co-injections, 100 j.iL of
Dns-Ornithine was added to 100 pt of dansylated enzyme assay containing [U-
14C]arginine and 150 j.iL injected into the HPLC.For analysis by positive FAB-
MS, a total of 10 x 100 jiL of dansylated assay, containing non-radioactive
substrate, was injected and the desired compound collected manually.The
solvent was removed in vacuo and submitted for mass-spectral analysis without
further purification.
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Chapter 4
Synthesis of L-[guanidino-13C]Capreomycidine and Incorporation Studies
using S. L-1689-23
Introduction
Capreomycidine (17) is an arginine-derived amino acid constituent found
in many members of the tuberactinomycin class of peptide antibiotics, including
capreomycinsIA(64,Figure4.1),lB(65),llA(66) andlIB(67),and
tuberactinomycins N (70) and tuberactinomycin 0 (71). Capreomycidine is also
a proposed intermediate in the biosynthesis of the streptolidine (15) moiety in
streptothricin F(12a).1While the chemical structure of capreomycidine was
proposed by Herr,2 Bycroft and coworkers proposed the stereochemistry of the
aminoacid.3The absolute configuration of capreomycidine was ultimately
determined through the x-ray analysis of tuberactinomycin456
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IA (64): R = OH, R' = -Lysine
lB (65): R = H,R' = 3-Lysine
hA (66): ROH, R' = H
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Tuberactinomycins
A (68): R = OH, R' = y-hydroxy-3-Lysine
B (69): R = OH, R' = 3-Lysine
N (70); R = H, R' = 'y-hydroxy-3-Lysine
0(71): R = H, R' = f3-Lysine
Figure 4.1. The Tuberactinomycin Class of Antibiotics93
The first synthesis of DL-capreomycidine (17, Figure 4.2) was
reported by Bycroft and coworkers and involved the hydrogenation and
hydrolysisof2-amino-4-(a-methoxycarbonyl-a-hydroxyimino)methylpyrimidine
(72).In an attempt to synthesize optically pure capreomycidine, Wakamiya and
coworkers first developed a synthesis of DL-capreomycidine starting from the
diethyl acetal of-aminopropionaldehyde, 73, to form the key intermediate-
hydroxyornithine (74) as a mixture ofdiastereomers.8This procedure was later
applied to the synthesis of enantiomerically pureL-capreomycidine.9It was
reported that the racemic threo diastereomer (74a) could be separated from the
racemic etythrodiastereomer(74b)viafractionalcrystallization.
Enantiomerically pure Cbz-protected-hydroxyornithine (75) was prepared by
chloroacetylation of racemic 74a followed by enzymatic resolution using acylase
(Scheme 4.1).-Hydroxyornithine (75) was then converted to (2S,3R)-
capreomycidine in nine successive steps with a 0.1 percent overall yield starting
from the protected aldehyde, 73.
Figure 4.2. The Structure of L-Capreomycidine (17) and Other Key
Intermediates Used in Prior Syntheses of 17
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In order to study biosynthetic pathways in which capreomycidine may be
involved, labeled forms of the amino acid are required.Stable isotopes, either
deuterium or 13C, should be located within the molecule at sites that would not be
lost due to racemization or other biochemical events.When introducing the
chemical label into a synthetic sequence, the label should be introduced as late
in the sequence as possible.Based on these criteria, a study wherein L-
[guanidino-13C]capreomycidineispreparedandusedinincorporation
experiments was designedtodetermine whether capreomycidineisan
intermediate in the biosynthesis of streptothricin F (12a).
Results and Discussion
Synthesis of L-fguanidino-13CJCapreomycidine (17)
Due to the enzymatic resolution step required in Wakamiya'ssynthesis9to
produce the key intermediate 74a, a more efficient synthesis of L-capreomycidine
was sought for our incorporationstudies.Scheme 4.2illustratesthe
retrosynthetic analysis used in designing a synthesis for L-capreomycidine.It
was envisioned that the guanidino moiety in capreomycidine results from the95
condensation of diamine 76 with cyanogen bromide.It was also recognized that
this would be the best step to introduce a 13C label into the amino acid. Diamine
76 could be obtained from diol 77 through functional group interconversion. Diol
77 can be derived from aldehyde 78 using a funtionalized Grignard reagent. The
corresponding aldehyde (78) can be derived by oxidation of di-protected L-serine
(79)
Scheme 4.2. Retrosynthetic analysis of L-Capreomycidine
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Instead of beginning directly with L-serine, use of the serine-derived
oxazolidine aldehydes 80 (Figure 4.3) or 81 as potential starting materials for the
synthesis of L-capreomycidine was examined. Oxazolidine aldehydes 80 and 81
are commonly referred to as Garner's aldehyde's and were first reported by
Garner and Park in 198710 with various modifications published over theyears.1'
13The synthesis of a Cbz-protected oxazolidine aldehyde has also been
reported,14but has attracted much less attention as synthetic starting material.
Both 80 and 81 have been used extensively in the synthesis of enantiomericallypure amino acids andderivatives,1525as well as natural products and their
derivatives.2634Currently, both isomers of Garner's aldehyde are commercially
available from Aldrich Chemical Company, but are too expensive to be used as
starting material on a large scale.Initially, the desired oxazolidine, 80, was
obtained from D-serine (82) using Garner'sprocedure1°as outlined in scheme
4.3. By using D-serine methyl ester (83), however, oxazolidine aldehyde 80 was
prepared more efficiently.
H H
NyO
80 81
Figure 4.3. (4R)- and (4S)-Oxazolidine Aldehydes (Garner's Aldehydes)Scheme 4.3. Synthesis of (4R)-Garner's Aldehyde
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The synthesis of L-capreomycidine was initiated as outlined in Scheme
4.4. Reaction of aldehyde 80 with allylmagnesiumchloride35cleanly produced a
diastereomeric mixture of the corresponding homoallylic alcohols, 86. Protection
of the secondary alcohols with tert-butyldimethylsilyl (TBDMS)chloride36afforded
the TBDMS-protected homoallylic alcohol(87)innear quantitativeyield.
Oxidative cleavage of the terminal double bond in 87 with ozone and in situ
reduction with sodiumborohydride,37afforded the desired primary alcohols, 88
and 89 in a 2:1 ratio, respectively. The diastereomers of 86 can be separated
after protection with tert-butyldimethylsilyl chloride using flash chromatography,
but the separation was tedious and difficult.Separation of the secondary
alcohols 88 and 89 was achieved with greater efficiency.Scheme 4.4 Synthesis of Primary Alcohols 88 and 89
>cOy
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1. 0, MeOH,
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clJ0x
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89
To determine the relative stereochemical outcome of the Grignard
reaction, the TBDMS-protected homoallylic alcohols were carefully purified by
flash chromatography to afford pure samples of each diastereomer. The major
diastereomer (87a) from the Grignard reaction wasdeprotected36to form 90a
(Scheme 4.5). Homoallylic alcohol 90a was then converted to the a-methoxy-a-
(trifluoromethyl)phenylacetateesters(MTPA)38'3991and92,respectively.
Analysis of the proton NMR spectra of both diastereomers by the advanced
Mosher'smethod4°(Table 4.1) resulted in the tentative assignment of the
stereochemistry of the major diastereomer 87a as presented in Figure 4.4.
Hafner and coworkers,intheirsynthesisofhomoallylic alcoholsusing
cyclopentadienyldialkoxyallyltitaniumcomplexes,havesynthesizedthe
enantiomer to87a.41Further support for the stereochemistry in 87a was
therefore obtained through a comparison of the spectral data of 87a to that of its
the enantiomer, which revealed near identical chemical shifts for both the proton
and carbon NMR spectral data.A further attempt to elucidate the absolutestereochemistry of the major diastereomer included conversion of primary
alcohol 88 to the corresponding p-nitrobenzoate derivative (93, Scheme 4.6), but
crystals of 93 could not be obtained.
Scheme 4.5 Synthesis of the (R)- and (S)-MTPA Esters of 87a
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Figure 4.4. A) The MTPA plane of the (R)-MTPA ester of a secondary alcohol.
B) The rulefordeterminingtheabsoluteconfigurationof secondary
alcohols(A6= 8s ER).C)The proposed stereochemistry for the major
diastereomer from the Grignard reaction.100
Table 4.1. 1H NMR analysis of the Mosher Esters 96 and 97.
Proton 6ppm (S)-MTPA ppm (R)-MTPA zppm (6S 6R)
10
6a ,b
12a,b
5a ,b
4
14a,b
13
11
P
1.4757 1.4640 0.012
1.6353 1.6604 -0.025
1.3909 1.4283 -0.037
2.5772 2.5428 0.034
2.3538 2.3136 0.040
3.8006 3.9157 -0.115
3.5259 3.6344 -0.109
4.0846 4.1178 -0.033
5.0244 4.9508 0.074
4.9697 4.8870 0.083
5.7397 5.6606 0.079
5.8439 5.8002 0.044
F3
O
6a'>ç
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Scheme 4.6. Synthesis of p-Nitrobenzoate Derivative 93 from 88
OTBDMS OTBDMS 0
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NO2101
The stereochemical outcome of the Grignard reaction can be rationalized
as depictedin Figure 4.5.The Felkin-Anh model for the addition of an
organometallic compound to a chiral aldehyde predicts that the major product
would result from attack of the nucleophile on the si-face of the aldehyde. This
direction of attack would lead toantiproduct.Conversely, if the metal were
chelated to the compound, as depicted in the Cram chelation model, nucleophilic
attack by the Grignard reagent at the re-face of the aldehyde would occur.
Based upon the analysis of the MTPA-esters of 90a, and a comparison with the
'3C NMR spectral data of its enantiomer, theantiaddition product is the major
diastereomer produced in the reaction. This suggests that chelation dictates the
predominant adduct.
0
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Figure 4.5. A) Felkin-Anh and B) Cram Chelation Model Illustrating Nucleophilic
Attack from the Least Encumbered Face.102
Initially, primary alcohol 88 was to be converted to the corresponding
primary azide via tosylation and nucleophilic displacement with sodium azide
(Scheme 4.7).Unfortunately, the tosylation proceeded very slowly with an
increase in the formation of side products over time. As a result, poor yields of
tosylate 94 were obtained.Displacement of the tosylate with sodium azide,
however, occurred cleanly and in high yield to generate the primary azide (95).
Attempts were made to optimize the reaction by testing different bases and
solvents (Table 4.2) but none of the conditions provided adequate yields for the
synthesis of the desired primary azide.
Scheme 4.7. Synthesis of Primary Azide 95 via Tosylation
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OTBDMS OTBDMS
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DMF
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95
Table 4.2. Tosylation Conditions Used in the Formation of 94
Entry No. Mol. eq. pTsCl Solvent Base Catalystt (hr) % Yeild
1 1.6 CHCI3PyridineDMAP 64 19
2 1.6 PyridinePyridine 48 41
3 1.6 PyridinePyridineDMAP 48 31
4 1.6 CHCI3 Et3N 64 29
5 1.6 CHCI3 Et3N DMAP 64 33
Although alkyl azide formation via a sulfonate ester is a common practice,
it was evident that an alternative route to azide 95 would need to be used. One103
potential method was to use diphenyiphosphoryl azide (DPPA) in the presence of
triphenyl phosphine (TPP) and diethylazodicarboxylate(DEAD).42This modified
Mitsunobu reaction has been applied towards the synthesis of a variety of
secondary azides4345746and therefore few problems were anticipated in the
conversion of alcohol 88 to azide 95. Also, the reaction was reported to proceed
with inversion ofconfiguration,42a feature that would be useful when converting
the secondary alcohols to the corresponding azides.When alcohol 88 was
exposed to the modified Mitsunobuconditions,47the corresponding primary azide
was obtained in high yield (Scheme 4.8). When these same conditions were
applied to diastereomer 89, the reaction again proceeded smoothly to form
primary azide 96.
Scheme 4.8. Synthesis of Primary Azides 95 and 96
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ih Primary azide 96 was deprotected (Scheme Ph,pPh
36 4.9) using tetra-n-butylammonium fluoride(TBAF) to
Et'
generate the secondary alcohol 97 (Scheme 4.9).
Compound 97 was subjected to the same Mitsunobu
Betaine 98 conditions usedinthe conversion of the primary
alcohols to the primary azides, changing only the order
thatreagentswereaddedtothereaction.
Unfortunately, no diazide was detected and only starting material was recovered.
There are reported cases in which the Mitsunobu reaction was unsuccessful in
inverting the stereochemistry of a secondary alcohol48,49 as well as converting a
secondary alcohol to the corresponding azide.5°It was suspected that alcohol 97
was unreactive under the modified Mitsunobu conditions due to the presence of
the large BOC group. The theory was that the BOC group may be positioned so
that the nucleophilic hydroxyl group was unable to react with betaine 98.5155
Diazide 99 was eventually obtained by converting 97 to the corresponding
methanesulfonate ester 100,56 followed by displacement with lithium azide.
Diazide 99 was reduced using TPP in wet tetrahydrofuran57 (THE) to cleanly
afford diamine 101.Condensation of 101 with [13C]BrCN58produced the
guanidino derivative 102 in moderate yield. Deprotection of the oxazolidine using
6 N HCI followed by reprotection with di-tert-butyldicarbonate (BOC) and
oxidation using potassium permanganate afforded L-capreomycidine (17) after
acidic workup.Scheme 4.9.Synthesis of L-Capreomycidine(17)from96.
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Of the different types of sulfonates, methanesulfonates are the
least reactive towards nucleophilicdisplacement.59This is due, in part, to the
lack of stabilization of the resulting sulfonate anion that is generated as a by-
product of theSN2reaction. Several attempts were made, therefore, to improve
the conversion of secondary alcohol97to diazide99 byexploring various
sulfonate esters. As presented in Table4.3(entry1),only the methanesulfonate
wasobtainedinadequateyields.Arecentreportontheuseof
chloromethanesulfonyl chloride(MCCI)as a much more efficient leaving group for
displacement with azide ion wasexamined.60Unfortunately, the secondary106
alcohol (102) did not react with McCl (entry 3). Attemps to convert the secondary
alcohol to the corresponding triflate (entry 4) was also unsuccessful.61
Table 4.3. Attempted Synthesis of Various Sulfonate
Esters from Alcohol 97
Entry no.Sulfonyl Chloridea % Yield % S.M.
1 MsCI 93 0
2 pTsCl 0 97
3 McCI 0 85
4 Tf20 0 0
aAbbreviations: MsCI = Methanesulfonyl Chloride; pTsCl = p-Toluenesulfonyl
Chloride; MCCI = Monochioromethanesulfonyl Chloride; Tf20 =Triflic Anhydride
Incorporation Studies Using (g uan idi no-13CJCapreomycidine
Enough [guanidino-'3C]capreomycidine (36 mg) was produced to allow
two incorporation studies.After generating production flasks containing S. L-
1689-23, 18 mg of labeled 17 was introduced into each of two 100 mL production
flasks and the STF produced was isolated 24 hours after initial innoculation.
Analysis of the purifiedantibiotic by '3C NMR spectroscopy showed no
appreciable incorporation into the guanidino carbon of STF.This experiment
was repeated using the remaining labeled material with similar results.Based
upon these findings,capreomycidineisnot atrueintermediateinthe
biosynthesis of streptolidine, oritis unable to enter the cell. Itis also
conceivable that a capreomycidine intermediate is enzyme-bound.107
Summary
Beginning with D-serine or D-serine methyl ester, a new synthesis of L-
capreomycidine has been established.The key intermediate in the synthesis
was the oxazolidine diazide, which was converted to capreomycidine in five
steps.While most of the steps in the synthesis produced high yields, the
conversion of the mesylate to the diazide was troublesome and proceeded in low
yield as did the final oxidation in the synthesis to produce capreomycidine.
Nonetheless, an adequate amount of capreomycidine containing a '3C label at
the guanidino position was synthesized and added to production flasks of S. L-
1689-23. Upon isolation of streptothricin F, no incorporation was detected. This
may indicate that synthetic capreomycidine did not enter the cells, is not a true
biosynthetic intermediate in the biosynthesis of streptolidine, or only occurs as an
enzyme bound intermediate.
Experimental
General
Fermentation conditions and media preparation used in the following
experiments were described in Chapter 2. All chemicals were purchased through
Aldrich Chemical Company or Arcos Chemical Company and used without
further purification. Sodium cyanide (99.99% 13C enriched) was purchased from
Cambridge Isotope Laboratories (Cambridge, MA). Anhydrous tetrahydrofuran,
benzene, and toluene were obtained by refluxing over sodium in the presence of
benzophenone. Anhydrous methanol was obtained by refluxing over magnesium
methoxide. Anhydrous dimethylformamide (DMF) was obtained by first letting
500 mL stand over 4Amolecular sieves for 24 hours.The DMF was thenI;
distilled under argon into a receiving vessel containing additional 4Amolecular
sieves. The DMF was stored under argon and used without further purification.
NMR spectra were obtained on either a BRUKER AC 300 or AM 400
spectrometer.t-BuOH or pyridine was added as an internal reference of
chemical shift when spectra were recorded in D20. Mass Spectra were obtained
on a Kratos MS 50 TL spectrometer.Optical rotations were obtained using a
Perkin-Elmer model 141 Polarimeter.IR spectra were obtained using a Nicolet
Model 510 FT-IR spectrometer.Ozone used for ozonolysis reactions was
generated using an OREC Ozone Generator (Ozone Research & Equipment
Corporation).
Synthesis of L-(guan idino-13CJCapreomycidine
N-f(1. 1-Dimethylethoxy)carbonyll-D-Serine Methyl Ester (84)
To a solution of D-serine 82 (10.0 g, 9.52 mmol) in 1.0 N NaOH (195 mL)
at 0 °C was added a solution of 1.20 eq Boc-anhydride (24.9 g, 1.14 mmol) in
I ,4-dioxane (89 mL) with stirring.After 30 minutes at 0 °C, the mixture was
warmed to room temperature over the course of four hours.Analysis by TLC
(hexanes/EtOAc, 1:1, detection: 0.2% ethanolic ninhydrin) showed complete
conversion of starting material (Rf 0.0) to product (R 0.34). The reaction mixture
was then concentrated to one-half the original volume and cooled back down to 0
°C. To the resulting solution was slowly added 1.0 N KHSO4 (240 mL) until the
pH was 2-3. The aqueous mixture was extracted with EtOAc (3 x 200 mL) and
the combined organic layers washed with brine (1 x 200 mL) and dried over
anhydrous MgSO4. Filtration and removal of the solvent afforded 19.5 g (100%)
of the desired compound as a sticky, colorless foam. The carbamate was used
without further purification.ip
To a solution of the Boc-protected amino acid (19.5 g, 0.952 mol) in 200
mL Et20 at 0 °C was bubbled gaseous diazomethane in nitrogen until the color of
the solution was yellow.Acetic acid was then slowly added (2.5 mL, N2
evolution) until the solution was colorless. The reaction mixture was washed with
half-saturated NaHCO3 (500 mL), brine (1 x 200 mL) and dried over MgSO4.
Filtration and removal of the solvent afforded a light yellow oil which was purified
by flash chromatography (hexanes/EtOAc, 1:1, 7 x 15 cm, detection: 0.2%
ethanolic ninhydrin) to afford 14.5 g (70%) of the desired product. [aj5-7.52°
(C6.08, CHCI3); IR (neat) 3400, 1720 (br)cm1;1H NMR (400 MHz, CDCI3, 25
°C) ö (ppm) 1.44 (s, 9H), 2.67 (bs, I H), 3.77 (s, 3H), 3.87 (dd, J = 4.0 and 11 Hz,
I H), 3.94 (dd, J = 4.0 and 11 Hz, 1 H) 4.37 (bs, I H), 5.48 (bs, I H); 13C NMR (100
MHz, CDCI3, 25 °C)(ppm) 28.2, 52.4, 55.7, 62.9, 80.1, 155.9, 171.6; MS
(FAB): m/z 220.2 (M + 1); HRMS (FAB): calcd forC9H18N05220.1185, obsd
220.1185.
Alternate route to N-f(1. 1-Dimethylethoxy)carbonylj-D-Serine Methyl
Ester (84)
To a stirred solution of D-serine methyl ester (83), 15.0 g, 9.60 mol) in 1.0
M NaHCO3 (280 mL, pH 9.3) at 0 °C was slowly added a solution of Boc-
anhydride (25.2 g, 0.116 mol) in dioxane (90 mL) over one-half hour.The
reaction mixture was removed from the ice-water bath and stirring continued for
an additional five hours. Analysis by TLC (hexanes/EtOAc, 1:1, detection: 0.2%
ethanolic ninhydrin) showed complete conversion of starting material (Rf 0.0) to
product (Rf 0.39). The reaction was concentrated to one-half the original volume
and cooled back down to 0 °C. Cold I M KHSO4 was slowly added until no more
carbon dioxide evolved and the pH of the solution was within the range of pH 1-2.
The mixture was washed with EtOAc (3 x 200 mL) and the combined organic
layers washed with saturated NaHCO3 (3 x 200 mL), brine (1 x 200 mL) and110
dried over Na2SO4. Filtration and removal of the solvent afforded 84, as a light
yellow oil (19.8 g, 94%), which was used without further purification.
3-(1. 1-Dimethylethyl) (4R)-4-methyl-2. 2-dimethyl-3,4-
oxazolidinecarboxylate (85)
To a solution of 84 (19.8 g, 9.03 mmcl) in dry benzene (314 mL) was
added 2,2-dimethoxypropane (22.2 mL, 0.188 mcI) followed by p-toluenesulfonic
acid (0.242 g, 1.27 mmol) and the solution refluxed at 90 °C for one-half hour. A
total of 269 mL of solvent was then slowly distilled off. Fresh benzene (125 mL)
and 2,2-dimethoxypropane (5.8 mL, 47.2 mmol) was added to the reaction
mixture and the procedure was repeated, this time collecting 100 mL of distilled
solvent.Analysis by TLC (hexanes/EtOAc, 1:1, detection: 0.2% ethanolic
ninhydrin) showed the complete conversion of starting material to product. The
reaction mixture was partitioned between saturated NaHCO3 (100 mL) and Et20
(600 mL). The organic layer was washed with saturated NaHCO3 (3 x 100 mL),
brine (1 x 100 mL), and dried over Na2SO4. Filtration and removal of the solvent
affordedcrudeproductthatwaspurifiedbyflashchromatography
(hexanes/EtOAc, 1:1, 7 x 15 cm column, detection: 0.2% ethanolic ninhydrin) to
afford 20.1 g (86%) of the desired product.[a5+56.2° (c 3.84, CHCI3); IR (neat)
2980, 1760, 1710, 1380cm1;1H NMR (300 MHz, C6D6, 70 °C) 6 (ppm) 1.40 (s,
9H), 1.56 (s, 3H), 1.84 (s, 3H), 3.33 (s, 3H), 3.73 (t, J = 8 Hz, I H), 3.81 (dd, J =
3.2 and 9.0 Hz, IH), 4.33 (m, 1H); '3C NMR (75 MHz, C6D6, 70 °C) 6 (ppm)24.8,
25.7, 28.2, 51.5, 59.6, 66.2, 95.2, 151.3, 171.3; MS (FAB): m/z 260.2 (M + 1);
HRMS (FAB): calcd for C12H22N05 260.1498, obsd 260.1499.Ill
1. 1-Dimethylethyl (4R)-4-formyl-2, 2-dimethyl-3-
oxazolidinecarboxylate (80)
To a stirred solution of the methyl ester 85 in dry toluene (150 mL) at -78
°C under argon atmosphere was added diisobutylaluminum hydride (1.50 M
solution in toluene, 88 mL, 0.132 mol) dropwise with stirring.After the addition
was complete, stirring was continued for another four hours at -78 °C. Analysis
of the reaction mixture by TLC (hexanes/EtOAc, 4:1, detection: 0.2% ethanolic
ninhydrin) showed nearly complete conversion of starting material (Rf 0.48) to
product (Rt 0.36). At this point, dry methanol (164 mL) was slowly added at -78
°C (H2 evolution). The milky solution was slowly poured into 190 mL of ice cold I
N HCI with stirring.The mixture was extracted with Et20 (3 x 500 mL), the
combined organic layers washed with brine (1 x 500 mL) and dried over Na2SO4.
Filtration and removal of the solvent produced crude product that was purified by
flash chromatography (hexanes/EtOAc, 4:1, 7 x 15 cm column, detection: 2%
Phosphomolybdic Acid (PMA)) to afford 15.9 g of the desired aldehyde (80).
[a5+93.O° (c 1.13, CHCI3); IR (neat) 2973, 1738, 1697, 1369cm1;1H NMR
(300 MHz, C6D6, 70 °C)(ppm) 1.38 (s, 9H), 1.44 (s, 3H), 1.62 (s, 3H), 2.10 (m,
IH), 2.19 (t, J6.2 Hz, 1H), 2.30 (m, 1H), 3.62 (dd, J = 6.2 and 9.2 Hz, IH), 3.69
(m, IH), 3.88 (m, 2H), 4.99 (t, J = 1.3 Hz, 1H), 5.05 (m, IH), 5.92 (m, IH); '3C
NMR (75 MHz, C6D6, 70 °C) ö (ppm) 24.5, 27.5, 28.8, 38.9, 39.2, 62.4, 64.9,
65.2, 72.4, 73.0, 80.5, 80.8, 94.8, 106.8, 117.3, 117.4, 136.0, 136.2, 153.7,
154.4; MS (FAB): m/z 272.35 (M + 1); HRMS (FAB): calcd for C14H26N04
272.1862, obsd 272.1860.112
1, 1-Dimethylethyl (4R)-(1 'hydroxy-3-butenyl)-2, 2-dimethyl-3-
oxazolidinecarboxylate (86)
To a solution of the aldehyde 80 (14.8 g, 6.45 mmol) in dry THF (350 mL)
at 78 °C was slowly added 3.3 eq allylmagnesium chloride (0.213 mol, 107 mL
of a 2 M solutionin THF) with stirring and then slowly warmed to room
temperature.Analysis by TLC (Hexanes/EtOAc; 3:1; detection: PMA) showed
complete conversion of starting material to product at R 0.38. Saturated
ammonium chloride (100 mL) was then added, and the mixture extracted with
ether (3 x 300 mL).The combined organic layers were washed with sat.
NaHCO4 (2 x 300 mL), brine (1 x 300 mL) and dried over MgSO4. Filtration and
removal of the solvent afforded the desired product, which was purified by flash
chromatography (hexanes/EtOAc; 3:1; 7 x 20 cm column; detection: PMA) to
afford15.0 g of the desiredhomoallylic alcohol(86) as a mixture of
diastereomers.[a5+28.8° (c 3.90, CHCI3); IR (neat) 3465 (br), 1696cm1;1H
NMR (300 MHz, C6D6, 70 °C) ö (ppm) 1.35 (s, 9H), 1.44 (s, 3H), 1.61 (s, 3H),
3.52 (t, J = 8.2 Hz, 1 H), 3.65 (d, J = 6.9 Hz, I H), 3.78 (m, 1 H), 9.33 (s, I H); '3C
NMR (75 MHz, C6D6, 70 °C)(ppm) 24.5, 26.5, 28.6, 64.0, 65.5, 80.9, 95.5,
152.0, 198.5; MS (FAB): m/z230.131 (M + 1); HRMS (FAB): calcd for C11H20N04
230.1392, obsd 230.1393.
1. 1-Dimethylethyl (4R1 I 'R)-(I 'L(tertbutyIdimethysiIyIoxy)3 -butenyI)-
2, 2-dimethyl-3-oxazolidinecarboxylate (88) and I, 1-Dimethylethyl
(4R. I 'S)-(l '-(tert-butyldimethvsilvloxv)-3 '-butenyI)-2, 2-dimethyl-3-
oxazolidinecarboxylate (89)
To 11.6 g (4.26 mmol) of the starting homoallylic alcohol in dry DMF (23.1
mL) was added imidazole (8.69 g, 0.128 mol) followed by tert-butyldimethysilyl
chloride (8.98 g, 0.06 mol) and the mixture was stirred at room temperature for
24 hours. Analysis by TLC (hexanes/EtOAc, 4:1, detection: 2% PMA) showed113
complete conversion of starting material (Rf 0.28) to product (Rf 0.81). Water
(100 mL) was added and the solution extracted with Et20 (3 x 500 mL). The
combined organic layers were washed with saturated NaHCO3 (3 x 500 mL),
brine (1 x 500 mL), and dried over Na2SO4. Filtration and removal of the solvent
afforded the diastereomers as a yellow oil (16.4 g, 100%). Both diastereomers
were separated by flash chromatography (pentane/Et20, 9:1, 7 x 21 cm column,
detection: 2% PMA) to afford 60% of the major diastereomer and 35% of the
minor diastereomer. (88, major diastereomer)[a5+27.10 (c 3.84, CHCI3); lR
(neat) 1702, 1384cm1;1H NMR (300 MHz, C6D6, 70 °C) ö (ppm) 0.11 (s, 3H),
0.12 (s, 3H), 0.84 (s, 9H), 1.42 (s, 9H), 1.46 (s, 3H), 1.70 (s, 3H), 2.31 (m, 1H),
2.49 (m, IH), 3.80 (dd, J = 7.2 and 9.3 Hz, 1H), 4.01 (bs, IH), 4.22 (dd, J = 2.2
and 9.4 Hz, IH) 4.01 (bs, IH), 5.07 (m, 2H), 5.91 (m, 1H); '3C NMR (75 MHz,
C6D6, 70 °C)(ppm) 18.6, 23.8, 26.5, 27.0, 29.0, 36.6, 61.7, 63.8, 72.2, 80.1,
95.3, 117.0, 137.3, 153.0; MS (FAB): m/z386.2 (M + 1); HRMS (FAB): calcd for
C20H40NO4Si 386.2727, obsd 386.2721. (89, minor diastereomer)[a5+50.7° (c
3.10, CHCI3); lR (neat) 1695, 1363, 1254cm1;1H NMR (300 MHz, C6D6, 70 °C)
ö(ppm) 0.10 (s, 3H), 0.14 (s, 3H), 0.97 (s, 9H), 1.41 (s, 9H), 1.65 (s, 3H), 1.66
(m, 3H), 3.62 (bs, 2H), 3.70 (dd, J= 7.1 and 8.1 Hz, IH), 3.98 (bs, IH), 4.13 (dd,
J = 3.3 and 8.4 Hz, IH), 4.36 (bd, J = 6.2 Hz, IH); '3C NMR (75 MHz, C6D6, 70
°C) 5 (ppm) -3.7, -3.7, 18.7, 25.2, 26.7, 27.5, 28.9, 38.9, 59.4, 62.0, 64.0, 70.0,
80.4, 94.9, 153.7; MS (FAB): m/z 386.2 (M + 1); HRMS (FAB): calcd for
C20H40N04S1 386.2727, obsd 386.2728.
1, 1-Dimethylethyl (4R. I 'R)-(I '-hydroxy-3'-butenyfl-2, 2-dimethyl-3-
oxazolidinecarboxylate (90)
To a solution of the TBDMS-protected homoallylic alcohol 87a (0.519 g,
1.34 mmol) in dry THF (16 mL) at room temperature was added a solution of114
tetra n-butylammonium fluoride in THF (3.36 mmol, 3.40 mL) with stirring. Upon
completion of the addition,stirring was continued for two hours at room
temperature. Analysis by TLC (hexanes/EtOAc, 3:1, detection: 12) showed the
desired product (Rf 0.19) at the expense of starting material.The reaction
mixture was partitioned between water (100 mL) and Et20 (150 mL). The organic
layer was washed with saturated NaHCO3 (3 x 100 mL), brine (1 x 100 mL), and
dried over MgSO4. Filtration and removal of the solvent afforded crude product
(372 mg). Purification by flash chromatography (hexanes/EtOAc, 2:1, detection:
12) afforded 363 mg (99%) of the desired product as an oil.[aj5+19.2° (c 0.66,
CHCI3); IR (neat) 3472 (br), 3081, 2978, 2931, 1690cm1;1H NMR (400 MHz,
C6D6, 67 °C)(ppm) 1.38 (s, 9H), 1.44 (s, 3H), 1.62 (s, 3H), 2.09 (m, 1H), 2.30
(m, IH), 3.62 (dd, J = 1.5 and 8.9 Hz, IH), 3.70 (bd, J = 9.2 Hz, IH), 3.91 (m,
IH), 5.00 (t, J = 1.3 Hz, IH), 5.04 (m, IH), 5.92 (m, IH); "3C NMR (100 MHz,
C6D6, 67 °C)(ppm) 24.6, 27.5, 28.8, 39.1, 62.4, 65.2, 73.2, 80.8, 94.8, 117.5,
135.8, 154.5; MS (Cl): m/z 272.1 (M + 1); HRMS (Cl): calcd for C14H26N04
272.1862, obsd 272.1863.
(R)-(+)-MTPA Ester of 1, 1-Dimethylethyl (4R, I 'R)-(I '-hydroxy-3 '-
butenyl)-2, 2-dimethyl-3-oxazolidinecarboxylate (91)
To a solution of the secondary alcohol 90 (0.093 g, 0.34 mmol) in dry
CH2Cl2 (2 mL) was added a catalytic amount of 4-dimethylamminopyridine (0.040
mmol, 5.0 mg), (R)-(+)-MTPA (0.391 mmol, 91 mg) and dicyclohexylcarbodiimide
(0.37 mmol, 0.37 mL of a I M solution in CH2Cl2) and the mixture was stirred
under argon for two hours.Analysis of the reaction mixture by TLC
(hexanes/EtOAc, 3:1, detection: UV, 12) showed conversion of the starting
material to a UV-active compound (Rf 0.56). The organic layer was washed with
saturated NH4OH (1 x 2 mL), sat. NaHCO3 (2 x 2 mL), brine (1 x 2 mL) and dried
over sodium sulfate.Filtration and removal of the solvent first afforded a dark115
yellow oil(143 mg), which was further purified by flash chromatography
(hexanes/EtOAc, 3:1, 1 x 15 cm column, detection: UV) to afford 100 mg (60%)
of the desired MTPA ester (91).[aj5 +29.2° (c 0.25, CHCI3); IR (neat)cm1;1H
NMR (300 MHz, C6D6, 70 °C)(ppm) 1.43 (s, 3H), 1.46 (s, 9H), 1.66 (s, 3H),
2.31 (m, IH), 2.54 (m, 1H), 3.37 (s, 3H), 3.63 (dd, J = 6.8 and 9.7 Hz, IH), 3.92
(dd, J= 1.7 and 9.9 Hz, IH), 4.12 (bs, 1H), 4.89 (d, J10Hz, IH), 4.95 (dd, J
1.3 and 17Hz, IH), 5.66 (m, IH), 5.80 (m, IH), 7.10(m, 3H), 7.64 (d, J= 7.2 Hz,
2H); 13C NMR (75 MHz, C6D6, 70 °C) ö (ppm) 23.5, 26.9, 28.8, 28.9, 33.7, 55.7,
58.8, 62.4, 64.1, 75.8, 81.0, 85.9, 95.4, 118.4, 122.8, 126.6, 130.2, 133.4, 133.8,
134.3, 152.8, 166.6; MS (FAB): m/z 488.2 (M + 1); HRMS (FAB): calcd for
C24H33F3N06 488.2260, obsd 488.2268.
(S)-(-)-MTPA Ester of 1, 1-D!methylethyl (4R. I 'R)-(I '-hydroxy-3'-
butenyl)-2, 2-dimethyl-3-oxazolidinecarboxylate (92)
Mosher ester 92 was prepared from the corresponding homoallylic alcohol
(90) and (S)-(-)-MTPA using the same procedure outlined for the synthesis of 91.
Using 99 mg (0.36 mmol) of 90, 210 mg of 92 (84%) was obtained.[aI5-28.9°
(c 0.55, CHCI3); IR (neat) 3074, 2984, 2939, 1752, 1711, 1376cm1;1H NMR
(300 MHz, C6D6, 70 °C)(ppm) 1.39 (s, 3H), 1.48 (s, 9H), 1.64 (s, 3H), 2.35 (m,
IH), 2.58 (m, IH), 3.44 (s, 3H), 3.53 (dd, J = 6.8 and 9.8 Hz), 3.80 (dd, J = 2.1
and 9.9 Hz), 4.08 (bs, I H), 4.97 (d, J = 11 Hz), 5.02 (m, 2H), 5.74 (m, I H), 5.84
(m, 1H), 7.08 (m, 3H), 7.64 (d, J = 7.9 Hz); 13C NMR (75 MHz, C6D6, 70 °C)
ö(ppm) 23.4, 26.8, 28.8, 33.3, 55.9, 58.4, 63.9, 75.6, 80.9, 85.8, 95.4, 118.3,
122.7, 126.6, 130.1, 133.5, 134.8, 152.7, 166.4; MS (FAB): mlz 488.2 (M + 1);
HRMS (FAB): calcd for C24H33F3N06 488.2260, obsd 488.2269.116
1. 1-Dimethylethyl (4R. I R)-4-(1 '-(tert-buty!dimethylsilyloxy)-3 '
hydorxypropy!)-2, 2-dimethyl-3-oxazo!idinecarboxylate (88)
To a solution of 87a (3.05 g, 0.0079 mol) in dry MeOH (106 mL) at -78 °C
was bubbled ozone until the solution turned blue/gray in color.The excess
ozone was removed by bubbling nitrogen through the solution at which point
sodium borohydride (0.30 g, 0.0079 mol) was added. The reaction was stirred at
-78 °C for one-half hour. This procedure was repeated twice more and then the
mixture was allowed to slowly reach room temperature.Stirring was then
continued at room temperature for twelve hours. The reaction was analyzed by
TLC (hexanes/EtOAc, 3:1, detection: 2% PMA), which showed the desired
product (Rf 0.55) at the expense of starting material.The excess sodium
borohydride was destroyed by slowly adding saturated NH4CI and then the
reaction mixture was transferred to a separatory funnel. The organic layer was
washed with saturated NaHCO3 (3 x 100 mL), brine (1 x 100 mL), and dried over
Na2SO4. Filtration and removal of the solvent generated a light yellow oil which
was purified by flash chromatography (hexanes/EtOAc, 3:1, 7 x 15 cm column,
detection: 2% PMA) to obtain 2.81 g (91%) of the desired primary alcohol (88).
[a5+17.9° (c 2.04, CHCI3); IR (neat) 3493 (br), 1691, 1391cm1;1H NMR (300
MHz, C6D6, 70°C)(ppm) 0.14 (s, 6H), 0.93 (s, 9H), 1.44 (s, 9H), 1.46 (s, 3H),
1.71 (bs, 4H), 1.85 (m, I H), 3.61 (t, J = 5.8 Hz, 2H), 3.81 (t, J = 7.8 Hz, I H), 3.93
(q, J = 7.3 Hz, IH), 4.02 (bs, IH) 4.19 (bd, J = 9.4 Hz, IH), 4.55 (bs, IH); 13C
NMR (75 MHz, C6D6, 70 °C) ö (ppm) -4.24, -3.71, 18.5, 23.9, 26.5, 26.9, 29.0,
34.7, 60.2, 61.4, 63.9, 69.5, 80.3, 95.3, 153.1; MS (FAB): m/z 390.3 (M + 1);
HRMS (FAB): calcd for C19H40NO5Si 390.2676, obsd 390.2675.117
1, 1-Dimethylethyl (4R, I S)-4-(1 '-(tert-butyldimethylsilyloxy)-3 '
hydroxypropyl)-2, 2-dimethyl-3-oxazolidinecarboxylate (89)
Compound 89 was prepared starting from diastereomer 87b (1.99 g, 5.16
mmol), employing the procedure described for 93. The primary alcohol 89 (Rf
0.46) was obtained in 94% yield (1.89 g):[aj54530 (c 0.96, CHCI3); IR (neat)
3457 (br), 1695, 1370cm1;1H NMR (300 MHz, C6D6, 70 °C)(ppm) 0.10 (s,
3H), 0.14 (s, 3H), 0.97 (s, 9H), 1.41 (s, 9H), 1.49 (s, 3H), 1.66 (s 3H), 1.67 (m,
3H), 3.62 (bs, 2H), 3.70 (dd, J = 6.9 and 8.2 Hz, IH), 3.98 (bs, IH), 4.13 (dd, J
= 3.4 and 8.4 Hz, I H), 4.36 (bd, J = 6.2 Hz, 1 H);13C NMR (75 MHz, C6D6, 70 °C)
ö (ppm) -3.73, 18.7, 25.2, 26.6, 27.5, 28.9, 38.9, 59.4, 62.0, 64.0, 70.0, 80.4,
94.9, 153.7; MS (FAB): m/z 390.3 (M + 1); HRMS (FAB): calcd for C19H40NO5Si
390.2676, obsd 390.2674.
1, 1-Dimethylethyl (4R, I R)-4-(I .(tert-butyIdimethyIsiIy!oxy)-3 '-(4-
nitrobenzyloxy)-dihydroxypropyl)-2, 2-d!methyl-3-
oxazolidinecarboxylate (93)
To a solution of the primary alcohol 88 (60 mg, 0.15 mmol) in dry pyridine
(10 mL) under an argon atmosphere at room temperature was added p-
nitrobenzoyl chloride (40 mg, 0.22 mmol) and the reaction mixture was stirred at
room temperature for one-half hour.Analysis of the reaction mixture by TLC
(Hexanes/EtOAc, 4:1, detection: PMA, UV) showed complete conversion of
starting material into a higher (Rf 0.67) UV-active component. The mixture was
transferred to a separatory funnel and partitioned between water (10 mL) and
CH2Cl2 (30 mL). The organic layer was washed with I M CuSO4 (3 x 15 mL),
water (3 x 15 mL), brine (1 x 15 mL) and then dried over anhydrous MgSO4.
Filtration and removal of the solvent afforded a dark yellow oil (100 mg), which
was purified by flash chromatography (Hexanes/EtOAc, 6:1, 15 x 1 cm column,118
detection: PMA, UV) to afford 76 mg (92%) of the benzylated primary alcohol, 93.
{a5+15.7°(C1.54, CHCI3); IR (neat) 3111, 3078, 3054, 2957, 2859, 1729, 1697
cm1;1H NMR (300 MHz, C6D6, 70 °C)(ppm) 0.12 (s, 6H), 0.46 (bs, IH), 0.93
(s, 9H), 1.37 (s, 9H), 1.43 (s, 3H), 1.70 (bs, 2H), 1.82 (m, IH), 2.16 (m, 1H), 3.80
(dd, J = 7.1 and 9.4 Hz, IH), 4.03 (m, IH), 4.17 (dd, J = 2.0 and 9.5 Hz, IH),
4.37 (m, 1H), 4.89 (m, IH), 7.78 (d, J = 6.8 Hz, 2H), 7.88 (d, J = 9.0 Hz); 13C
NMR (75 MHz, C6D6, 70 °C)(ppm) -4.30, -3.67, 18.5, 24.0, 26.4, 27.1, 28.9,
31.0, 61.5, 63.6, 68.4, 80.4, 95.2, 123.8, 131.0, 136.3, 151.4, 153.0, 164.9; MS
(Cl): m/z 539 (M + 1); HRMS (Cl): calcd for C26H43N2O8Si 539.2789, obsd
539.2778.
1, 1-Dimethylethyl (4R. I R)-4-(I '-(tert-butyldimethylsilyloxy)-3 (p-
toluenesu!fonyloxy)-dihydroxypropyl)-2, 2-dimethyl-3-
oxazolidinecarboxylate (94)
A total of 2.48 g (6.36 mmol) of the primary alcohol (88) were dissolved in
dry pyridine (200 mL) followed by the addition of p-toluenesulfonyl chloride (1.94
g, 10.2 mmol) and the mixture stirred at room temperature under argon for
twenty-four hours. Analysis of the reaction mixture by TLC (hexanes/EtOAc, 4:1,
detection: PMA, UV) showed complete depletion of starting material so the
reaction was transferred to a 1 L separatory funnel and CHCI3 was added. The
organic layer was quickly washed with cold 1 N HCI (3 x 200 mL) followed by
water. The organic phase was then washed with saturated NaHCO3 (3 x 200
mL) and brine (1 x 200 mL). The organic layer was dried over sodium sulfate,
filtered, and the solvent removed to afford a dark brown syrup.The crude
material was purified by flash chromatography (hexanes/EtOAc, 4:1, 6 x 16 cm
column, detection: PMA, UV) to afford 1.61g (46%) of the desired primary
tosylate (94).[a5+54.6° (c 2.82, CHCI3); IR (neat) 2928, 1693cm1;1H NMR
(300 MHz, C6D6, 70 °C) ö (ppm) 0.09 (s, 6H), 0.92 (s, 9H), 1.41 (s, 3H), 1.45 (s,119
9H), 1.60 (s, 3H), 1.92 (s, 3H), 2.05 (m, IH), 3.73 (dd, J = 7.2 and 9.4 Hz), 3.95
(bs, 1H), 4.04 (dd, J = 1.7 and 9.4 Hz), 4.20 (q, J = 5.2 Hz, IH), 4.48 (m, IH),
6.81 (d, J = 8.0 Hz), 7.75 (d, J = 8.2 Hz); 13C NMR (75 MHz, C6D6, 70 °C) ö (ppm)
-4.3, -3.7, 18.5, 21.4, 23.6, 26.4, 26.9, 28.9, 31.7, 61.1, 63.5, 68.2, 80.6, 95.4,
130.1, 130.2, 135.5, 144.4, 153.0; MS (Cl): m/z415.1 (M + 1); HRMS (Cl): calcd
for C19H39N4O4Si 415.2741, obsd 415.2734.
1, 1-Dimethyleth VI (4R. I R)-4-(3 '-azido-I '-(tert-butyldimethyls!Iyloxy)-
prop yl)-2. 2-dimeth yI-3-oxazolidinecarboxylate (95)
To a solution of the 94 99 (1.61 g, 2.96 mmol) in dry DMF (40 mL) was
added sodium azide (0.291 g, 4.44 mmol) and the mixture stirred at 90 °C for two
hours. Analysis of the reaction mixture by TLC (hexanes/EtOAc, 4:1, detection:
UV, PMA) showed complete conversion of starting material (Rf 0.42) to a high Rf
compound (Rf 0.64).Upon cooling to room temperature, the mixture was
partitioned between CH2Cl2 (75 mL) and water (75 mL). The organic layer was
washed with saturated NaHCO3 (2 x 100 mL), brine (1 x 100 mL), and dried over
sodium sulfate.Filtration and removal of the solvent afforded a yellow oil, which
was purified by flash chromatography (Hexanes/EtOAc, 4:1, 15 x 4 cm column,
detection: PMA)to afford 1.18 g of the desired primary azide (95). [a5+47.9° (c
2.6, CHCI3); IR (neat) 2097, 1691cm1;1H NMR (300 MHz, C6D6, 70 °C)(ppm)
0.10 (s, 6H), 0.90 (s, 9H), 1.44 (s, 12H), 1.68 (s, 3H), 1.86 (m, IH), 3.12 (m, 2H),
3.75 (t, J = 8.0 Hz, 1H), 3.98 (bs, 1H), 4.10 (d, J = 9.4 Hz, 1H), 4.44 (bs, IH); 13C
NMR (75 MHz, C6D6, 70 °C)(ppm) -4.32, -3.72, 18.5, 23.7, 26.4, 26.9, 28.9,
30.8, 48.9, 61.3, 63.6, 68.8, 80.4, 95.3, 152.9; MS (FAB): m/z 415.1 (M + 1);
HRMS (FAB): calcd for C19H39N4O4Si 415.2741, obsd 415.2737.120
1. 1-Dimethylethy! (4R. I R)-4-(3 '-azido-(I '-tert-butyldimethylsilyloxy)-
I '-hydroxypropyl)-2, 2-dimethyl-3-oxazo!idinecarboxylate (95) via
Modified Mitsunobu Conditions
To a solution of the primary alcohol 88 (5.24 g, 0.0134 mol) in dry THF
(200 mL) under argon atmosphere at 0 °C was added triphenylphosphine (4.23
g, 1.61 mmol) followed by diethylazodicarboxylate (2.5 mL, 1.61 mmol) and the
mixture stirred at 0 °C in the dark for one-half hour.Diphenylphosphoryl azide
(3.5 mL, 1.61 mmol) was then slowly added and the reaction mixture gradually
warmed to room temperature, and then stirred in the dark overnight. Analysis of
the reaction mixture by TLC (hexanes/EtOAc, 3:1, detection: 2% PMA) showed
complete conversion of starting material to product (Rf 0.82). The solvent was
removedandtheresultingoilwaspurifiedbyflashchromatography
(hexanes/EtOAc, 4:1, 7 x 15 cm column, detection: 2% PMA) to afford 5.03 g
(90%) of the desired azide (95).All physical data was identical to the primary
azide prepared via nucleophilic displacement of the tosylate with sodium azide.
I, 1-Dimethylethyl (4R. I 'S)-4-(3 'azido-(I -tert-butyld!methylsily!oxy)-
I -hydroxypropyfl-2, 2-dimethyl-3-oxazolidinecarboxylate (96)
Diastereomer 96 was synthesized from compound 89 (1.89 g, 4.85 mmol),
utilizing the Mitsunobu procedure outlined for the preparation of 95. The desired
azide 96 (Rf 0.75) was obtained in 90% yield (1.80 g).[a5 26.3° (c 2.48,
CHCI3); IR (neat) 2092, 1697 cm1; 1H NMR (300 MHz, C6D6, 70 °C)(ppm) 0.06
(s, 3H), 0.10 (s, 3H), 0.93 (s, 9H), 1.43 (s, 9H), 1.49 (s, 3H), 1.68 (s, 2H), 3.11
(m, I H), 3.26 (bs, I H), 3.61 (dd, J = 6.7 and 8.2 Hz), 3.76 (bs, I H), 4.00 (dd, J =
2.5 and 8.5 Hz), 4.17 (q, J4.7 Hz); 13C NMR (75 MHz, C6D6, 70 °C) ö (ppm) -
4.35, -4.25, 18.1, 24.4, 26.0, 27.3, 28.4, 34.2, 47.7, 61.2, 63.8, 69.8, 79.8, 94.4,121
153.0; MS (Cl): m/z 415.1 (M + I); HRMS (Cl): calcd for C19H39N4O4Si 415.2736,
obsd 415.2741.
1, 1-Dimethylethyl (4R, I 'S)-4-(3 -azido-I '-hydroxypropyl)-2, 2-dim ethyl-
3-oxazolidinecarboxylate (97)
To a solution of the TBDMS-protected alcohol 96 (6.39 g, 1.54 mmol) in
dry THF (129 mL) at room temperature was added tetra-n-butylammonium
fluoride (1 M soln in THF, 38.5 mL, 3.85 mmol) and the mixture stirred at room
temperature for 2.5 hours. Analysis by TLC (hexanes/EtOAc, 4:1, detection: 2%
PMA) showed complete conversion of starting material to product (Rf 0.18). The
mixture was partitioned between water (200 mL) and Et20 (500 mL).The
organic layer was washed with sat. NaHCO3 (2 x 200 mL), brine (1 x 200 mL),
and dried over MgSO4.Filtration and removal of the solvent afforded a light
yellow oil (7.63 g), which was purified by flash chromatography (Hexanes/EtOAc,
4:1, 7 x 15 cm column, detection: 2% PMA). A total of 4.33 g (94%) of the
desired product (97) was obtained.[a5+24.3° (c 1.21, CHCI3); IR (neat) 3451,
2099, 1695cm1;1H NMR (400 MHz, C6D6, 70 °C) 6 (ppm) 1.33 (s, 9H), 1.36 (s,
3H), 1.41 (m, IH), 1.48 (m, IH), 1.52 (s, 3H), 3.15 (m, 2H), 3.54 (bd, J = 5.6 Hz),
3.69 (m, IH), 3.77 (bs, IH); 13C NMR (100 MHz, C6D6, 70 °C) 6 (ppm) 24.4, 27.2,
28.7, 33.2, 49.2, 62.9, 65.2, 70.9, 81.0, 95.0, 154.3; MS (Cl): m/z 301 .1 (M + 1);
HRMS (Cl): calcd for C13H25N404 301.1876, obsd 301.1878.
I, 1-Dimethyl (4R. I 'S)-4-(1 i'methanesulfonyIoxy)-3 -azido-propyl)-2, 2-
dimethyl-3-oxazolidinecarboxylate (100).
The secondary alcohol 97 was dissolved in dry CH2Cl2 (6.0 mL) followed
by the addition of dry triethylamine (1.22 mL, 8.74 mmol). The solution was122
cooled to -48 °C and then methanesulfonyl chloride (0.260 mL, 3.30 mmol) was
added dropwise with stirring over fifteen minutes.The reaction was slowly
allowed to warm up to 0 °C over the course of two hours.Analysis of the
reaction mixture by TLC (hexanes/EtOAc, 3:1, detection: 2% PMA) showed
complete conversion of starting material (Rf 0.33) to a lower Rf compound (Rf
0.28). The reaction was partitioned between water (35 mL) and CH2Cl2 (75 mL)
and then the organic layer was washed with water (1 x 35 mL), and dried over
anhydrous magnesium sulfate.Filtration and removal of the solvent afforded a
dark yellowoil(942 mg), which was purifiedby flash chromatography
(hexanes/EtOAc, 2:1, 15 x 3cm column, detection: PMA) to afford 615 mg of the
desired mesylate (100).[a5+23.8° (c 1.34, CHCI3); IR (neat) 2107, 1692cm1;
1H NMR (400 MHz, C6D6, 70°C) ö (ppm) 1.41(S, 9 H), 1.43 (s, 3H), 1.62 (s, 3H),
2.41(s, 3H), 3.08 (m, 2H), 3.56 (dd, J = 6.8 and 9.0 Hz, IH), 3.75 (bs, IH), 3.79
(dd, J = 3.8 and 9.1 Hz, IH), 5.17 (m, IH); 13C NMR (100 MHz, C6D6, 70 °C) ö
(ppm) 24.6, 27.1, 28.7, 32.4, 38.6, 48.1, 60.2, 63.7, 78.2, 81.0, 95.3, 153.0; MS
(Cl): m/z 379 (M + 1); HRMS (CI): calcd for C14H27N406S 379.1651, obsd
379.1656.
1. 1-Dimethylethyl (4R. I 'S)-4-I ' 3 -diazidopropyl)-2. 2-dimethyl-3-
oxazolidinecarboxylate (99)
The secondary mesylate 100 (3.04 g, 8.03 mmol) was dissolved in dry
dimethylformamide (80 mL) followed by the addition of lithium azide (1.04 g, 21.3
mmol).The mixture was heated at 90 °C for twenty-four hours and then
monitored by TLC (hexanes/EtOAc, 3:1, detection: 2% PMA), which showed the
conversion of starting material to a major component at R 0.78. The reaction
mixture was transferred to a separatory funnel and partitioned between water
(200 mL) and Et20 (500 mL). The organic layer was washed with water (2 x 200
mL), brine (1 x 200 mL) and dried over sodium sulfate.Filtration and removal of123
the solvent afforded a dark yellow oil (1.41 g), which was purified by flash
chromatography (hexanes/EtOAc, 7:1, 7 x 18 cm column, detection: 2% PMA) to
afford 0.917 g (35%) of the desired product (99). [a5 +37.2° (c 1.15, CHCI3); IR
(neat) 2146, 2098, 1697cm1;1H NMR (400 MHz, C6D6, 70°C)(ppm) 1.18 (m,
2H), 1.40 (s, 9H), 1.47 (s, 3H), 1.68 (s, 3H), 2.84 (m, 2H), 3.50 (m, IH), 3.68 (dd,
J = 3.2 and 9.4 Hz, 1H), 4.00 (bs, IH); '3C NMR (100 MHz, C6D6, 70 °C) ö (ppm)
23.3, 26.8, 28.4, 28.9, 48.7, 59.7, 61.2, 64.0, 80.5, 94.9, 152.4; MS (Cl): m/z
326.2 (M + 1); HRMS (Cl): calcd for C13H24N703 326.1941, obsd 326.1940.
1, 1-Dimethylethyl (4R. I 'S)-4-(1 '3 '-diam!nopropy!)-2 , 2-dimethyl-3-
oxazo!id!necarboxylate (101)
To a solution of the diazide 99 (0.917 g, 2.82 mmol) in THE (25 mL) was
added triphenylphosphine (2.01 g, 6.18 mmol) and water (0.11 g, 6.18 mmol) and
the mixture refluxed for sixteen hours.Analysis of the reaction mixture by TLC
(CH2Cl2/MeOH/NH4OH, 8:1:1,detection: 0.2% ethanolic ninhydrin) showed
complete conversion of starting material to product at Rf 0.24. The solvent was
removed, and theresultingyellowoil(3.15g) waspurifiedby flash
chromatography (CH2Cl2/MeOH/NH4OH, 8:1:1; column = 4 x 15 cm, detection:
0.2% ethanolic ninhydrin) to afford the desired diamine (101, 0.700 g, 100%) as
yellow oil.[aI5+26.2°(C2.10, CHCI3); IR (neat) 3405 (br), 1693cm1;1H NMR
(300 MHz, C6D6, 70°C) ö 0.71 (bs, 5H), 1.14 (m, 1H), 1.29 (m, IH), 1.42 (s, 9H),
1.52 (s, 3H), 1.67 (s, 3H), 2.64 (bs, I H), 3.09 (bs, I H), 3.28 (bs, I H), 3.62 (t, J =
8.4 Hz, IH), 3.69 (bs, IH), 3.83 (dd, J = 1.9 and 8.5 Hz, IH); '3C NMR (75 MHz,
C6D6, 70 °C) ö 24.4, 27.5, 28.9, 38.8, 40.5, 51.3, 63.2, 64.2, 80.0, 94.5, 153.3;
MS (FAB): m/z 274.1 (M + 1); HRMS (FAB): calcd for C13H28N303 274.2131,
obsd 274.2133.124
L-fquan idi no-13CjCapreomycidine
A crude cyanogen bromide solution (2 mmol in 4 mL water) was slowly
added to a solution of the diamine 101 (0.200 g, 0.730 mmol) in 21 mL water at
pH 11.5 over 2.5 hours.During the addition, the reaction was continually
adjusted to pH 11.5 using I N NaOH whenever the pH of the solution fell below
11.0.Upon completion of the addition, the mixture was stirred at room
temperature for an additional hour and then transferred to a separatory funnel.
The aqueous solution was extracted with Et20 (3 x 100 mL), the combined
organic layers were washed with water (1 x 100 mL), and then the aqueous
washings were combined. The solvent from the aqueous washes was removed
to afford a white, oily residue (1.05 g).The residue was washed with 100%
ethanol (3 x 25 mL) and the solvent from the washings was removed in vacuo to
afford a light tan residue (0.686 g). The residue was dissolved in water (8 mL)
and 2 mL of the solution was loaded onto a Varian Mega Bond Elute C18 column
(500 mg). The column was washed with water (3 x 3 mL) followed by elution with
acetonitrile with 3 mL fractions being collected.The collected fractions were
analyzedby TLC (n-BuOH/H20/AcOH,4:2:1,detection:0.2%ethanolic
ninhydrin). Those fractions that contained the cyclized product at Rf 0.79 were
pooled and the solvent removed to afford 150 mg of the desired productas the
hydrobromide salt.Based upon 13C NMR, the crude material was about 95%
pure.
The crude residue was dissolved in 6 N HCI (10 mL) and allowed to stand
for two hours at room temperature.Analysis of the solution by TLC (n-
BuOH/H20/AcOH, 4:2:1,detection: 0.2% ethanolic ninhydrin) showed the
conversion of starting material (Rf 0.82) to a ninhydrin-positive spot at the origin,
so the solvent was removed and the resulting residue was dissolved in I M
NaOH (5 mL) and cooled to 4 °C.To this was added BOC-anhydride (2.19
mmol, 480 mg) in dioxane (5 mL). The reaction was stirred at room temperature
for four hours and then potassium permanganate (1.40 mmol, 64 mg)was added125
and the mixture stirred for an additional six hours.The manganese dioxide was
filtered off and then the filtrate was acidified with 6 N HCI to pH 1. After standing
at room temperature for two hours, the solvent was removed to afford a white
residue (140 mg). The residue was dissolved in water (25 mL) and then loaded
onto an AG5OW-X8 column (H form, 13 x 2.5 cm) and then the column was
washed with water (300 mL). The column was then eluted with a pH gradient
(pH 7-9) of 0.14 NH4OAc, taking 10 mL fractions.Those fractions that were
ninhydrin-positive were pooled and the solvent removed to afford 15 mg (10%
from diamine 106) of the desired amino acid, L-capreomycidine. 1H NMR (300
MHz, D20, 25 °C)(ppm) 2.05 (m, 1 H), 2.21 (m, I H), 3.49 (m, 2H), 3.90 (d, J =
5.3 Hz, IH), 4.12 (m, 1H); '3C NMR (75 MHz, D20, 25 °C)(ppm) 23.4, 37.9,
50.1, 58.2, 156.0, 172.4; MS (FAB): m/z 174.1 (M + 1); HRMS (FAB): calcd for
C513CH13N402 174.1072, obsd 174.1073.
Incorporation Study Using (guanidino-13CJCapreomycidine (17), First
Experiment
The generation of seed and production media for S. L-1689-23 has been
described in Chapter 2. A total of 2 100 mL production flasks were prepared and
inoculated with 8% seed medium, which had been prepared 64 hours earlier.
The inoculated production flasks were incubated at 29 °C and 225 rpm for 12
hours, whereupon, 18 mg of [guanidino-13C]capreomycidine in 2 mL Milli-Q water
was divided between the two flasks and added aseptically via passage through a
sterile filter. The production flasks were incubated at 29 °C and 225 rpm for an
additional 36 hours and then worked up as previously described.After
purification, a total of 13 mg of STF was obtained. The isolated antibiotic was
analyzed by 13C NMR spectroscopy.126
Incorporation Study Using (guandi no-13CJCapreomycid!ne (17),
Second Experiment
Using the remaining 18 mg of [guanidino-13C]capreomycidine, a second
incorporation study was performed as described previously. From a total of 200
mL of production medium was obtained only 8 mg of antibiotic. The antibiotic
was analyzed by 13C NMR spectroscopy to determine the extent of incorporation.
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Chapter 5
Conclusions and Areas of Further Study
Through a combined approach using whole-cell incorporation studies and
cell-free investigations, the intermediacy of streptolidine (15) and capreomycidine
(17) in the biosynthesis of streptothricin F was investigated.From the results
describedinthe previous chapters, the biosynthetic pathway leading to
streptothricin F has been re-evaluated.
Scheme 5.1. Summary of the Biosynthetic Pathway to STF (12a)
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As shown in Scheme 5.1, the intermediacy of 15 in the biosynthesis of 12a
has been confirmed through studies using [guanidino-13C]streptolidine. From the
observed incorporation of labeled 15, additional support for a convergent
biosynthesis of 12a has been obtained.
The intermediacyof capreomycidine(17)inthebiosynthesisof
streptolidine was also examined using cell-free extracts of Streptomyces L-1689-
23. A HPLC protocol for the analysis of enzyme assays was developed and
enzyme activity related to the formation of three compounds was observed. Two
of the trhree compounds were identified as citrulline and ornithine, products
formed from the degradation of arginine.One possible enzyme known to
catalyze the conversion of arginine to citrulline is arginine deiminase, which has
not been previously identified in Streptomyces.
To further probe whether capreomycidine is an intermediate to 15, a new
synthesis of 17 was developed.Using Garner's aldehyde (85), (2S,3R)-
[guanidino-13C]capreomycidine was synthesized and introduced to production
cultures of S. L-1689-23.No incorporation of labeled 17 was observed.
Because the incorporation study was performed with a single pulse of labeled
compound, itis possible that the enzyme(s) responsible for the formation of
streptolidine were not present at the time 17 was administered. Future work with
capreomycidine may be successful if multiple pulses are administered prior to
isolation of the antibiotic.
The current synthesis of capreomycidine, while efficient in the early steps,
turned out to be inefficient at the end of the synthetic sequence. One possible
way around this problem may be to change the order in which reaction with
cyanogen bromide and final oxidation occur.Prior to reduction of the diazide
(104), selective deprotection could afford primary alcohol 108, which could then
be oxidized to the carboxylic acid (109). After protection of the acid as an amide
(110), the azides could be reduced to afford the desired diamine 111. Addition of
cyanogenbromidefollowedbyacidhydrolysisshouldthengenerate
capreomycidine.Scheme 5.2. Alternate Route to Capreomycidine via Diazide 104
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If the oxazolidine was deprotected at the stage of the primary azide (100,
Scheme 5.3), the formation of the diazide (110) from the corresponding mesylate
(112) might also be improved.Scheme 5.3. Alternate Route to Capreomycidine via Azide 100
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If adequate amounts of capreomycidine can be obtained, the intermediacy
of capreomycidine in the biosynthesis of the tuberactinomycin class of antibiotics,
capreomycidine 1A and lB can also be examined.
To further identify potential biosynthetic intermediates in the formation of
streptothricin F (12a), inhibitors of enzymes expected to be involved in the
biosynthesis of 12a could be added to production flasks of S. L-1689-23. This
approach has been successful in identifying intermediates inblasticidin S
biosynthesis.{ } Potential enzymes that could be targeted are those involved in
lysine biosynthesis, lysine 2,3-aminomutase and carbamoylphosphate synthase.
Aliquots of production medium obtained after introduction of the inhibitor could be
derivatized as described in chapter two and analyzed using our HPLC protocol.
One additional experiment that can also be proposed is testing if (4R)-
hydroxycapreomycidine is a reasonable intermediate to 15. This compound could
be used to determine when the oxidation that C-4 occurs in the conversion of
arginine to streptolidine.134
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